C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\2323tg.str



chain nodes :
12 13 14 15 16 27 28 29 30 31 33
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 22 23 24 25 26
chain bonds :
6-22 12-13 23-27 25-28 28-29 29-30 30-31 30-33
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-11 9-11 9-10 22-23
22-26 23-24 24-25 25-26
exact/norm bonds :
2-7 3-10 6-22 7-8 8-11 9-11 9-10 12-13 22-23 22-26 23-24 23-27
24-25 25-26 25-28 28-29 29-30 30-31 30-33
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 22 :

G1:[*1],[*2],[*3],[*4]

G2:CH3,Et

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 22:Atom
23:Atom 24:Atom 25:Atom 26:Atom 27:CLASS 28:CLASS 29:CLASS 30:CLASS
31:CLASS 33:CLASS

C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\55651.str





chain nodes :
6 7 8 9 10 15 18
ring nodes :
1 2 3 4 5
chain bonds :
1-18 2-6 4-7 7-15
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 1-18 2-3 2-6 3-4 4-5 7-15
exact bonds :
4-7

G1:[*1],[*2],[*3]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 15:CLASS 18:Atom
Generic attributes :
18:
Saturation : Unsaturated

Element Count :
Node 18: Limited
C,C3-11
N,N0-4
O,O0-3

L23 ANSWER 21 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:575073 HCAPLUS
DOCUMENT NUMBER: 137:140512
TITLE: Preparation of benzoheterocyclyloxazolidinones as antibacterial agents.
INVENTOR(S): Johnson, Paul D.; Aristoff, Paul A.; Poel, Toni-Jo; Thomasco, Lisa M.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002059115	A1	20020801	WO 2001-US42944	20011114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2421583	AA	20020801	CA 2001-2421583	20011114
US 2002133021	A1	20020919	US 2001-992660	20011114
US 6972286	B2	20051206		
EP 1337530	A1	20030827	EP 2001-997007	20011114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004517929	T2	20040617	JP 2002-559417	20011114
NZ 525918	A	20051125	NZ 2001-525918	20011114
US 2004176609	A1	20040909	US 2004-804389	20040319
US 2004186293	A1	20040923	US 2004-804380	20040319
PRIORITY APPLN. INFO.:			US 2000-249550P	P 20001117
			US 2001-992660	A3 20011114
			WO 2001-US42944	W 20011114

OTHER SOURCE(S): MARPAT 137:140512
GI



I

AB Title compds. [I; Y = NHC(:W)R1, OZ, SZ, NHZ; X = O, NR3, S, SO, SO2, S(O)(NR4); W = O, S; R1 = H, alkyl, cycloalkyl, alkoxy, alkylthio, amino;

Updated Search

R2 = H, halo, alkyl; R3 = H, alkyl, aryl, Z, etc.; R4 = H, alkyl; Z = (substituted) (aromatic) heterocyclyl; with provisos], were prepared Thus, N-[[(5S)-3-(1,2,3,4-tetrahydro-6-isoquinolinyl)-2-oxo-5-oxazolidinyl]methyl]acetamide (preparation given) and NaHCO3 in THF were treated with MeO2CCl with vigorous stirring. H2O was added and the mixture was stirred 1 h to give Me (-)-6-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-3,4-dihydro-2(1H)-isoquinolinecarboxylate. The latter showed a min. inhibitory concentration of 1 μg/mL against Streptococcus pneumoniae SPNE9912.

IT 444588-30-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of benzoheterocyclyloxazolidinones as antibacterial agents)

RN 444588-30-1 HCAPLUS

CN 2H-2-Benzazepine-2-carboxylic acid, 7-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,3,4,5-tetrahydro-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 444587-37-5P 444587-38-6P 444587-39-7P
444587-40-0P 444587-46-6P 444587-48-8P
444587-52-4P 444587-55-7P 444587-56-8P
444587-57-9P 444587-58-0P 444587-60-4P
444587-61-5P 444587-62-6P 444587-63-7P
444587-64-8P 444587-65-9P 444587-66-0P
444587-67-1P 444587-68-2P 444587-69-3P
444587-70-6P 444587-71-7P 444587-72-8P
444587-73-9P 444587-74-0P 444587-75-1P
444587-76-2P 444587-77-3P 444587-78-4P
444587-79-5P 444587-80-8P 444587-81-9P
444587-83-1P 444587-84-2P 444587-85-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzoheterocyclyloxazolidinones as antibacterial agents)

RN 444587-37-5 HCAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 6-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-3,4-dihydro-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Updated Search



RN 444587-38-6 HCAPLUS
CN Acetamide, N-[[(5S)-3-(2-formyl-1,2,3,4-tetrahydro-6-isoquinolinyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444587-39-7 HCAPLUS
CN Acetamide, N-[[(5S)-3-[2-[(acetyloxy)acetyl]-1,2,3,4-tetrahydro-6-isoquinolinyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444587-40-0 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-[1,2,3,4-tetrahydro-2-(hydroxyacetyl)-6-isoquinolinyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Updated Search



RN 444587-46-6 HCAPLUS
CN Acetamide, N-[[(5S)-3-(3,4-dihydro-1H-2-benzopyran-6-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444587-48-8 HCAPLUS
CN Acetamide, N-[[(5S)-3-(3,4-dihydro-1H-2-benzothiopyran-6-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444587-52-4 HCAPLUS
CN Acetamide, N-[[(5S)-3-(3,4-dihydro-1H-2-benzothiopyran-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444587-55-7 HCAPLUS
CN Acetamide, N-[[(5S)-3-(3,4-dihydro-2-oxido-1H-2-benzothiopyran-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Updated Search

Absolute stereochemistry.



RN 444587-56-8 HCAPLUS
CN Acetamide, N-[[(5S)-3-(3-formyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444587-57-9 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-(hydroxyacetyl)-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444587-58-0 HCAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Updated Search



RN 444587-60-4 HCAPLUS
CN Acetamide, N-[[(5S)-3-(3-acetyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444587-61-5 HCAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444587-62-6 HCAPLUS
CN Acetamide, N-[[(5S)-3-(3-benzoyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Updated Search



RN 444587-63-7 HCAPLUS
CN Acetamide, N-[[(5S)-3-[3-(5-amino-1,3,4-thiadiazol-2-yl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444587-64-8 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-(methylsulfonyl)-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444587-65-9 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-[5-(methylthio)-1,3,4-thiadiazol-2-yl]-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Updated Search



RN 444587-66-0 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-(5-methyl-1,3,4-thiadiazol-2-yl)-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444587-67-1 HCAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-, phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444587-68-2 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-(phenylacetyl)-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Updated Search



RN 444587-69-3 HCAPLUS
CN Acetamide, N-[[(5S)-3-[3-[5-(formylamino)-1,3,4-thiadiazol-2-yl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444587-70-6 HCAPLUS
CN Acetamide, N-[5-[7-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-1,3,4-thiadiazol-2-yl]-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444587-71-7 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-[(4-iodophenyl)acetyl]-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Updated Search



RN 444587-72-8 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-[[3-(trifluoromethyl)phenyl]acetyl]-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444587-73-9 HCAPLUS
CN Benzoic acid, 4-[(dimethylamino)methyl]-, 2-[7-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444587-74-0 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-[[4-(trifluoromethyl)phenyl]acetyl]-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Updated Search

Absolute stereochemistry. Rotation (-).



RN 444587-75-1 HCAPLUS
CN Acetamide, N-[[(5S)-3-[3-(1,4-dioxopentyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444587-76-2 HCAPLUS
CN Acetamide, N-[[(5S)-3-[3-(1,5-dioxohexyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444587-77-3 HCAPLUS
CN Acetamide, N-[[(5S)-3-(2-formyl-2,3,4,5-tetrahydro-1H-2-benzazepin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Updated Search



RN 444587-78-4 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-2-(hydroxyacetyl)-1H-2-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444587-79-5 HCAPLUS
CN Acetamide, N-[[(5S)-3-(2-acetyl-2,3,4,5-tetrahydro-1H-2-benzazepin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444587-80-8 HCAPLUS
CN 2H-2-Benzazepine-2-carboxylic acid, 7-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,3,4,5-tetrahydro-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Updated Search



RN 444587-81-9 HCAPLUS
CN 2H-2-Benzazepine-2-carboxamide, 7-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,3,4,5-tetrahydro-N-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444587-83-1 HCAPLUS
CN Acetamide, N-[[(5S)-3-(1-formyl-2,3,4,5-tetrahydro-1H-1-benzazepin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444587-84-2 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3-benzothiepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 444587-85-3 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3,3-dioxido-3-benzothiepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 444587-91-1P 444587-92-2P 444588-02-7P
444588-04-9P 444588-08-3P 444588-20-9P
444588-21-0P 444588-27-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzoheterocyclyloxazolidinones as antibacterial agents)
RN 444587-91-1 HCAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 6-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-3,4-dihydro-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444587-92-2 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-(1,2,3,4-tetrahydro-6-isoquinolinyl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 444588-02-7 HCAPLUS
CN Acetamide, N-[[(5S)-3-(3,4-dihydro-2,2-dioxido-1H-2-benzothiopyran-6-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444588-04-9 HCAPLUS
CN Acetamide, N-[[(5S)-3-(3,4-dihydro-1H-2-benzopyran-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444588-08-3 HCAPLUS
CN Acetamide, N-[[(5S)-3-(3,4-dihydro-2,2-dioxido-1H-2-benzothiopyran-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444588-20-9 HCAPLUS
CN 1H-1-Benzazepine-1-carboxylic acid, 7-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,3,4,5-tetrahydro-, phenylmethyl ester (9CI) (CA INDEX

Updated Search

NAME)

Absolute stereochemistry.



RN 444588-21-0 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1H-1-benzazepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444588-27-6 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\lmlmp.str





chain nodes :
1 8 9 10 11 12 14
ring nodes :
3 4 5 6 7
chain bonds :
1-3 4-8 6-9 9-10 10-11 11-12 11-14
ring bonds :
3-4 3-7 4-5 5-6 6-7
exact/norm bonds :
1-3 3-4 3-7 4-8 10-11 11-12 11-14
exact bonds :
4-5 5-6 6-7 6-9 9-10
isolated ring systems :
containing 3 :

G1

G2:CH3,Et

Match level :
1:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 14:CLASS
Generic attributes :
1:
Saturation : Unsaturated
Number of Carbon Atoms : 7 or more
Type of Ring System : Polycyclic

L23 ANSWER 29 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:511162 HCAPLUS
DOCUMENT NUMBER: 131:144608
TITLE: Preparation of New oxazolidinones with azo-containing tricycles as antimicrobial agents
INVENTOR(S): Raddatz, Siegfried; Bartel, Stephan; Guarnieri, Walter; Rosentreter, Ulrich; Ruppelt, Martin; Wild, Hanno; Endermann, Rainer; Kroll, Hein-peter; Henninger, Kerstin
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 207 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9940094	A1	19990812	WO 1999-EP518	19990127
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19805117	A1	19990812	DE 1998-19805117	19980209
AU 9925195	A1	19990823	AU 1999-25195	19990122
EP 1054889	A1	20001129	EP 1999-904817	19990127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002502854	T2	20020129	JP 2000-530523	19990127
PRIORITY APPLN. INFO.:			DE 1998-19805117 A	19980209
			WO 1999-EP518 W	19990127

OTHER SOURCE(S): MARPAT 131:144608
GI

Updated Search



I



II

AB The present invention relates to new oxazolidinones with azo-containing tricycles, to methods for producing the same as well as to the use thereof as drugs, in particular as anti-bacterial drugs. Title compds. [I; R = NHAc, NHCOCH2Cl, NHCOOMe, NH2, NHCOCHCl2, NHCOEt, NHCOCCl3, NHCSNH2, NHCSNHMe, NHCONH2, NHCHO, NHCSMe, NHCOOBu-t, NHCSOMe, NHCSOEt, OH, 3-NO2C6H4SO2O; A = O, CH2, S; B = CH2, (CH3)2C, S, O, S:O, SO2, CF2; B-A = S, CH2, CH:CH; X = CH, CCH3, N, CBr; Y = N, CCH3, CPh, CCOOEt, CCF3, CNHCOOBu-t, CBr, CCH2OH; Z = N, CCOOEt, CH], enantiomers, and salts are prepared as antibacterial drugs, tested against Staphylococcus aureus, Mycobacterium smegmatis, and Streptococcus pneumoniae. Thus, the title compound II was prepared from (5S)-3-(2-aminobenzthiazol-6-yl)-5-acetylaminomethyl-oxazolidin-2-one and CH2ClCHO via cyclization and tested.

IT 235789-77-2P 235789-78-3P 235789-79-4P
235789-80-7P 235789-81-8P 235789-82-9P
235789-83-0P 235789-85-2P 235789-86-3P
235789-87-4P 235789-88-5P 235789-89-6P
235789-90-9P 235789-91-0P 235789-92-1P
235789-93-2P 235789-94-3P 235789-95-4P
235789-96-5P 235789-97-6P 235789-98-7P
235789-99-8P 235790-00-8P 235790-01-9P
235790-02-0P 235790-03-1P 235790-04-2P
235790-17-7P 235790-18-8P 235790-19-9P
235790-26-8P 235790-27-9P 235792-17-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolidines substituted with bicycles as antimicrobial agents)

RN 235789-77-2 HCAPLUS

CN Acetamide, N-[[(5S)-2-oxo-3-(4H-[1,2,4]triazolo[3,4-c][1,4]benzoxazin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 235789-78-3 HCAPLUS
CN Propanamide, N-[[(5S)-3-(1-methyl-4H-[1,2,4]triazolo[3,4-c][1,4]benzoxazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235789-79-4 HCAPLUS
CN Acetamide, N-[[(5S)-3-(4,5-dihydro[1,2,4]triazolo[4,3-a]quinolin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235789-80-7 HCAPLUS
CN Acetamide, N-[[(5S)-3-(1-methyl-4H-imidazo[2,1-c][1,4]benzoxazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 235789-81-8 HCAPLUS
CN Acetamide, N-[[(5S)-3-(2-methyl-4H-imidazo[2,1-c][1,4]benzoxazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235789-82-9 HCAPLUS
CN Acetamide, N-[[(5S)-3-(4H-imidazo[2,1-c][1,4]benzoxazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235789-83-0 HCAPLUS
CN Propanamide, N-[[(5S)-3-(4H-imidazo[2,1-c][1,4]benzoxazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 235789-85-2 HCAPLUS
CN Acetamide, N-[[(5S)-3-imidazo[2,1-b]benzothiazol-7-yl-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235789-86-3 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-(2-phenylimidazo[2,1-b]benzothiazol-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235789-87-4 HCAPLUS
CN Imidazo[2,1-b]benzothiazole-2-carboxylic acid, 7-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 235789-88-5 HCAPLUS
CN Acetamide, N-[[(5S)-3-(2-methylimidazo[2,1-b]benzothiazol-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235789-89-6 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-[2-(trifluoromethyl)imidazo[2,1-b]benzothiazol-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235789-90-9 HCAPLUS
CN Acetamide, N-[[(5S)-3-(2,3-dimethylimidazo[2,1-b]benzothiazol-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

RN 235789-91-0 HCAPLUS
CN Acetamide, N-[[(5S)-3-[3-methyl-2-(trifluoromethyl)imidazo[2,1-b]benzothiazol-7-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235789-92-1 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-(4H-pyrrolo[2,1-c][1,4]benzoxazin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235789-93-2 HCAPLUS
CN Acetamide, N-[[(5S)-3-(4,4-dimethyl-4H-imidazo[2,1-c][1,4]benzoxazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235789-94-3 HCAPLUS
CN Acetamide, N-[[(5S)-3-(4H-imidazo[2,1-c][1,4]benzothiazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 235789-95-4 HCAPLUS
CN Acetamide, N-[[(5S)-3-(5H-imidazo[1,2-a][3,1]benzothiazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235789-96-5 HCAPLUS
CN 4H-Imidazo[5,1-c][1,4]benzoxazine-3-carboxylic acid, 7-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235789-97-6 HCAPLUS
CN Acetamide, N-[[(5S)-3-(4H-imidazo[5,1-c][1,4]benzoxazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 235789-98-7 HCAPLUS
CN Acetamide, N-[[(5S)-3-(9H-imidazo[1,2-a]indol-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235789-99-8 HCAPLUS
CN Acetamide, N-[[(5S)-3-(9H-imidazo[1,2-a]indol-7-yl)-2-oxo-5-oxazolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 235790-00-8 HCAPLUS
CN Acetamide, N-[[(5S)-3-(5H-imidazo[1,2-a][3,1]benzoxazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 235790-01-9 HCAPLUS
CN Carbamic acid, [7-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-4H-imidazo[2,1-c][1,4]benzoxazin-2-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235790-02-0 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-(4H-pyrazolo[5,1-c][1,4]benzoxazin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235790-03-1 HCAPLUS
CN Acetamide, N-[[(5S)-3-(4-oxido-5H-imidazo[1,2-a][3,1]benzothiazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 235790-04-2 HCAPLUS
CN Acetamide, N-[[(5S)-3-(4,4-dioxido-5H-imidazo[1,2-a][3,1]benzothiazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235790-17-7 HCAPLUS
CN Acetamide, N-[[(5S)-3-(1-bromo-4H-imidazo[2,1-c][1,4]benzoxazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235790-18-8 HCAPLUS
CN Acetamide, N-[[(5S)-3-(1,2-dibromo-4H-imidazo[2,1-c][1,4]benzoxazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 235790-19-9 HCAPLUS
CN Acetamide, N-[[(5S)-3-(4,4-difluoro-4H-imidazo[2,1-c][1,4]benzoxazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235790-26-8 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-(4H-tetrazolo[5,1-c][1,4]benzoxazin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235790-27-9 HCAPLUS
CN Acetamide, N-[[(5S)-3-[2-(hydroxymethyl)-4H-imidazo[2,1-c][1,4]benzoxazin-7-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 235792-17-3 HCAPLUS
CN Acetamide, N-[[(5S)-3-imidazo[1,2-a]quinolin-7-yl-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 235791-13-6P 235791-18-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oxazolidines substituted with bicycles as antimicrobial agents)
RN 235791-13-6 HCAPLUS
CN Acetamide, N-[[(5S)-3-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4H-imidazo[2,1-c][1,4]benzoxazin-7-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 235791-18-1 HCAPLUS
CN Acetamide, N-[[(5S)-3-(2-amino-6-benzothiazolyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 30 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:487539 HCAPLUS
DOCUMENT NUMBER: 131:129999
TITLE: Preparation of oxazolidines substituted with bicycles as antimicrobial agents
INVENTOR(S): Bartel, Stephan; Guarnieri, Walter; Haebich, Dieter; Raddatz, Siegfried; Riedl, Bernd; Rosentreter, Ulrich; Ruppelt, Martin; Stolle, Andreas; Wild, Hanno; Endermann, Rainer; Kroll, Hein-Peter
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Ger. Offen., 88 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19802239	A1	19990729	DE 1998-19802239	19980122
WO 9937641	A1	19990729	WO 1999-EP96	19990109
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9926161	A1	19990809	AU 1999-26161	19990109
EP 1049692	A1	20001108	EP 1999-906112	19990109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002501065	T2	20020115	JP 2000-528563	19990109
PRIORITY APPLN. INFO.:			DE 1998-19802239 A	19980122
			WO 1999-EP96 W	19990109

OTHER SOURCE(S): MARPAT 131:129999
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; R = Me, Et, COOMe, (CH3)2CH, R1 = H; R-R1 = (CH2)3; R3 = OH, OSO2Me, N3, NH2, NHCONH2, NHAc, NHCOCH2Br, NHCOOMe, NHCOEt, NHCOCF3, NHCOOBu-t, cyclopropylcarbonylamino, 2-furylcarbonylamino, NHP(OMe)2:O, etc.; X = C:O, CH2, S, S:O, SO2; Y = CH2, CHCH3, NMe, C:O, C6H5CH:C,

Updated Search

C6H5CH2C:, 4-ClC6H4CH:C, 4-MeOC6H4CH:C, etc.; Z = O, CH2], enantiomers, and salts are prepared Thus, the title compound II was prepared from 7-nitro-2H-1,4-benzoxazin-3-one, C6H5CH2OCONHCl, and (R)-(-)-glycidyl butyrate via reduction cyclization and was tested against Staphylococcus aureus, Mycobacterium smegmatis, and Streptococcus pneumoniae.

IT 233773-77-8P 233773-82-5P 233774-47-5P
233775-01-4P 233775-06-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oxazolidines substituted with bicycles as antimicrobial agents)

RN 233773-77-8 HCAPLUS

CN 4H-1,4-Benzoxazine-4-carboxylic acid, 7-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,3-dihydro-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 233773-82-5 HCAPLUS

CN Acetamide, N-[[(5S)-3-(3,4-dihydro-4-methyl-2H-1,4-benzoxazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233774-47-5 HCAPLUS

CN Acetamide, N-[[(5S)-3-(3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 233775-01-4 HCAPLUS
CN Acetamide, N-[[(5S)-3-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233775-06-9 HCAPLUS
CN Acetamide, N-[[(5S)-3-[3,4-dihydro-4-methyl-3-oxo-2-(phenylmethylene)-2H-1,4-benzothiazin-7-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



IT 233773-46-1P 233773-49-4P 233773-60-9P
233773-61-0P 233773-68-7P 233773-69-8P
233773-83-6P 233773-84-7P 233773-85-8P
233773-92-7P 233773-97-2P 233773-98-3P
233774-06-6P 233774-07-7P 233774-14-6P
233774-15-7P 233774-21-5P 233774-22-6P
233774-28-2P 233774-29-3P 233774-48-6P
233774-50-0P 233774-55-5P 233774-56-6P
233774-59-9P 233774-60-2P 233775-02-5P
233775-03-6P 233775-04-7P 233775-05-8P
233775-07-0P 233775-08-1P 233775-09-2P
233775-10-5P 233775-15-0P 233775-16-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

Updated Search

study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of oxazolidines substituted with bicycles as antimicrobial agents)

RN 233773-46-1 HCAPLUS
CN Acetamide, N-[[(5S)-3-(3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzoxazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233773-49-4 HCAPLUS
CN Propanamide, N-[[(5S)-3-(3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzoxazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233773-60-9 HCAPLUS
CN Propanamide, N-[[(5S)-3-(4-ethyl-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

RN 233773-61-0 HCAPLUS
CN Acetamide, N-[[(5S)-3-(4-ethyl-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233773-68-7 HCAPLUS
CN Propanamide, N-[[(5S)-3-(3,4-dihydro-2,4-dimethyl-3-oxo-2H-1,4-benzoxazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233773-69-8 HCAPLUS
CN Acetamide, N-[[(5S)-3-(3,4-dihydro-2,4-dimethyl-3-oxo-2H-1,4-benzoxazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233773-83-6 HCAPLUS
CN Acetamide, N-[[(5S)-3-(3,4-dihydro-4-methyl-2H-1,4-benzoxazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



●x HCl

RN 233773-84-7 HCAPLUS
CN Propanamide, N-[[(5S)-3-(3,4-dihydro-4-methyl-2H-1,4-benzoxazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233773-85-8 HCAPLUS
CN Propanamide, N-[[(5S)-3-(3,4-dihydro-4-methyl-2H-1,4-benzoxazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

Updated Search

RN 233773-92-7 HCAPLUS
CN 4H-1,4-Benzoxazine-4-carboxylic acid, 7-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,3-dihydro-, methyl ester (9CI) (CA INDEX NAME)



RN 233773-97-2 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-(2,3,6,7-tetrahydro-3-oxo-5H-pyrido[1,2,3-de]-1,4-benzoxazin-9-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233773-98-3 HCAPLUS
CN Propanamide, N-[[(5S)-2-oxo-3-(2,3,6,7-tetrahydro-3-oxo-5H-pyrido[1,2,3-de]-1,4-benzoxazin-9-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233774-06-6 HCAPLUS

Updated Search

CN Acetamide, N-[[(5S)-2-oxo-3-(2,3,6,7-tetrahydro-5H-pyrido[1,2,3-de]-1,4-benzoxazin-9-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233774-07-7 HCAPLUS
CN Propanamide, N-[[(5S)-2-oxo-3-(2,3,6,7-tetrahydro-5H-pyrido[1,2,3-de]-1,4-benzoxazin-9-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233774-14-6 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-(1,2,3,4-tetrahydro-1-methyl-2-oxo-6-quinolinyl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233774-15-7 HCAPLUS
CN Propanamide, N-[[(5S)-2-oxo-3-(1,2,3,4-tetrahydro-1-methyl-2-oxo-6-quinolinyl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Updated Search

Absolute stereochemistry.



RN 233774-21-5 HCAPLUS
CN Acetamide, N-[[(5S)-3-(1-ethyl-1,2,3,4-tetrahydro-2-oxo-6-quinolinyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233774-22-6 HCAPLUS
CN Propanamide, N-[[(5S)-3-(1-ethyl-1,2,3,4-tetrahydro-2-oxo-6-quinolinyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233774-28-2 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-[1,2,3,4-tetrahydro-1-(1-methylethyl)-2-oxo-6-quinolinyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 233774-29-3 HCAPLUS
CN Propanamide, N-[[(5S)-2-oxo-3-[1,2,3,4-tetrahydro-1-(1-methylethyl)-2-oxo-6-quinolinyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233774-48-6 HCAPLUS
CN Acetamide, N-[[(5S)-3-(3,4-dihydro-4-methyl-1,1-dioxido-2H-1,4-benzothiazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233774-50-0 HCAPLUS
CN Propanamide, N-[[(5S)-3-(3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 233774-55-5 HCAPLUS
CN Acetamide, N-[[(5S)-3-(2-ethyl-3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233774-56-6 HCAPLUS
CN Propanamide, N-[[(5S)-3-(2-ethyl-3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233774-59-9 HCAPLUS
CN Acetamide, N-[[(5S)-3-(3,4-dihydro-2,4-dimethyl-3-oxo-2H-1,4-benzothiazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 233774-60-2 HCAPLUS
CN Propanamide, N-[[(5S)-3-(3,4-dihydro-2,4-dimethyl-3-oxo-2H-1,4-benzothiazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233775-02-5 HCAPLUS
CN Acetamide, N-[[(5S)-3-(4-ethyl-3,4-dihydro-3-oxo-2H-1,4-benzothiazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233775-03-6 HCAPLUS
CN Acetamide, N-[[(5S)-3-[3,4-dihydro-4-(1-methylethyl)-3-oxo-2H-1,4-benzothiazin-7-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 233775-04-7 HCAPLUS
CN Acetamide, N-[[(5S)-3-(3,4-dihydro-4-methyl-1,1-dioxido-3-oxo-2H-1,4-benzothiazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233775-05-8 HCAPLUS
CN Acetamide, N-[[(5S)-3-(3,4-dihydro-4-methyl-1-oxido-3-oxo-2H-1,4-benzothiazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233775-07-0 HCAPLUS
CN Acetamide, N-[[(5S)-3-[2-[(4-chlorophenyl)methylene]-3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-7-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

Updated Search



RN 233775-08-1 HCAPLUS
CN Acetamide, N-[[(5S)-3-[3,4-dihydro-2-[(4-methoxyphenyl)methylene]-4-methyl-3-oxo-2H-1,4-benzothiazin-7-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 233775-09-2 HCAPLUS
CN Acetamide, N-[[(5S)-3-[3,4-dihydro-4-methyl-3-oxo-2-(4-pyridinylmethylene)-2H-1,4-benzothiazin-7-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 233775-10-5 HCAPLUS
CN Acetamide, N-[[(5S)-3-[3,4-dihydro-4-methyl-3-oxo-2-(phenylmethyl)-2H-1,4-benzothiazin-7-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 233775-15-0 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-(1,2,3,4-tetrahydro-1,3-dimethyl-2-oxo-6-quinazolinyl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233775-16-1 HCAPLUS
CN Propanamide, N-[[(5S)-2-oxo-3-(1,2,3,4-tetrahydro-1,3-dimethyl-2-oxo-6-quinazolinyl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 234084-87-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of oxazolidines substituted with bicycles as antimicrobial agents)
RN 234084-87-8 HCAPLUS
CN Acetamide, N-[[(5S)-3-(3,4-dihydro-2H-1,4-benzothiazin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



L23 ANSWER 31 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:487536 HCAPLUS
DOCUMENT NUMBER: 131:129985
TITLE: Oxazolidines substituted by tricyclic indoles
INVENTOR(S): Ruppelt, Martin; Bartel, Stephan; Guarnieri, Walter; Raddatz, Siegfried; Rosentreter, Ulrich; Wild, Hanno; Endermann, Rainer; Kroll, Hein-Peter
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Ger. Offen., 40 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19802235	A1	19990729	DE 1998-19802235	19980122
WO 9937652	A1	19990729	WO 1999-EP97	19990109
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9924206	A1	19990809	AU 1999-24206	19990109
EP 1049701	A1	20001108	EP 1999-903616	19990109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002501073	T2	20020115	JP 2000-528573	19990109
PRIORITY APPLN. INFO.:			DE 1998-19802235 A	19980122
			WO 1999-EP97 W	19990109

OTHER SOURCE(S): MARPAT 131:129985
GI

Updated Search



I

AB Approx. 25 antibacterial title compds. such as I (R = benzyl, p-methoxybenzyl, allyl, Bu, cyclohexyl, Et, Me; R1 = Ac, EtCO, CO2Me) were prepared E.g., N-[3-(2-(ethoxycarbonyl)-5-indolylamino)-2-hydroxypropyl]acetamide was cyclized with carbonyldiimidazole to give 85% 3-(2-ethoxycarbonyl-5-indolyl)-5-(acetaminomethyl)-2-oxazolidinone. The MIC of I (R = Bu, R1 = Ac) was 4 μg/mL against Staphylococcus Aureus.

IT 234770-13-9P 234770-20-8P 234770-22-0P
234770-24-2P 234770-26-4P 234770-28-6P
234770-29-7P 234770-35-5P 234770-37-7P
234770-39-9P 234770-40-2P 234770-42-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal activity of oxazolidines substituted by tricyclic indoles)

RN 234770-13-9 HCAPLUS

CN Acetamide, N-[[(5S)-3-(3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-8-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234770-20-8 HCAPLUS

CN Acetamide, N-[[3-[2,3-dihydro-1,3-dioxo-2-(2-propenyl)-1H-imidazo[1,5-a]indol-7-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 234770-22-0 HCAPLUS

CN Acetamide, N-[[3-(2-butyl-2,3-dihydro-1,3-dioxo-1H-imidazo[1,5-a]indol-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Updated Search



RN 234770-24-2 HCAPLUS
CN Acetamide, N-[[3-(2-ethyl-2,3-dihydro-1-oxo-3-thioxo-1H-imidazo[1,5-a]indol-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 234770-26-4 HCAPLUS
CN Acetamide, N-[[(5S)-3-(3,4-dihydro-1-oxo-1H-[1,4]oxazino[4,3-a]indol-8-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234770-28-6 HCAPLUS
CN Propanamide, N-[[(5S)-3-(3,4-dihydro-1-oxo-1H-[1,4]oxazino[4,3-a]indol-8-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234770-29-7 HCAPLUS

Updated Search

CN Acetamide, N-[[3-(2,3-dihydro-2-methyl-3-oxo-1H-imidazo[1,5-a]indol-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 234770-35-5 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-(1,2,3,4-tetrahydro-2-methyl-1-oxopyrazino[1,2-a]indol-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234770-37-7 HCAPLUS
CN Propanamide, N-[[(5S)-2-oxo-3-(1,2,3,4-tetrahydro-2-methyl-1-oxopyrazino[1,2-a]indol-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234770-39-9 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-(1,2,3,4-tetrahydro-2-methyl-3-oxopyrazino[1,2-a]indol-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 234770-40-2 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-(1,2,3,4-tetrahydro-2-methyl-1,4-dioxopyrazino[1,2-a]indol-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234770-42-4 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-(1,2,3,4-tetrahydro-1-oxopyrazino[1,2-a]indol-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 234770-47-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and bactericidal activity of oxazolidines substituted by tricyclic indoles)
RN 234770-47-9 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 5-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



Updated Search

IT 234770-15-1P 234770-17-3P 234770-23-1P
234770-25-3P 234770-41-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and bactericidal activity of oxazolidines substituted by tricyclic indoles)

RN 234770-15-1 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-1,3-dioxo-2-(phenylmethyl)-1H-imidazo[1,5-a]indol-7-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 234770-17-3 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-2-[(4-methoxyphenyl)methyl]-1,3-dioxo-1H-imidazo[1,5-a]indol-7-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 234770-23-1 HCAPLUS
CN Acetamide, N-[[(5S)-3-(2-cyclohexyl-2,3-dihydro-1,3-dioxo-1H-imidazo[1,5-a]indol-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234770-25-3 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-2-methyl-1,3-dioxo-1H-imidazo[1,5-a]indol-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Updated Search



RN 234770-41-3 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-(1,2,3,4-tetrahydro-2-methyl-1,3,4-trioxopyrazino[1,2-a]indol-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L23 ANSWER 32 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:487281 HCAPLUS
DOCUMENT NUMBER: 131:116228
TITLE: Preparation of oxazolidinones as bactericides
INVENTOR(S): Gordeev, Mikhail F.; Luehr, Gary W.; Patel, Dinesh V.; Ni, Zhi-Jie; Gordon, Eric
PATENT ASSIGNEE(S): Versicor, Inc., USA
SOURCE: PCT Int. Appl., 229 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9937630	A1	19990729	WO 1999-US1318	19990122
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2318969	AA	19990729	CA 1999-2318969	19990122
AU 9924644	A1	19990809	AU 1999-24644	19990122
AU 764184	B2	20030814		
EP 1049682	A1	20001108	EP 1999-904193	19990122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

Updated Search

JP 2002501059	T2	20020115	JP 2000-528553		19990122
BR 9907183	A	20030610	BR 1999-7183		19990122
NZ 505902	A	20030829	NZ 1999-505902		19990122
PRIORITY APPLN. INFO.:			US 1998-12535	A	19980123
			US 1998-86702	A	19980528
			WO 1999-US1318	W	19990122

OTHER SOURCE(S): MARPAT 131:116228
GI



I

AB Title compds. [e.g., I; R = H; R1 -SR11, CONR7R8, etc.; R7,R8. R11 = H, alkyl, (hetero)aryl, etc.] were prepared Thus, 3,4-F(Me3CO2C)C6H3NHCO2CH2Ph (preparation given) was cyclocondensed with (R)-glycidyl butyrate and the product converted in several steps to I (R = resin, R1 = CO2C6F5) which was amidated by morpholine to give, after resin cleavage, I (R = H, R1 = CONHR8, R8 = morpholino). Data for biol. activity of I were given.

IT 232950-89-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oxazolidinones as bactericides)

RN 232950-89-9 HCAPLUS

CN Acetamide, N-[[(5S)-2-oxo-3-[1-(triphenylmethyl)-1H-indazol-5-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 33 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	1999:421579 HCAPLUS
DOCUMENT NUMBER:	131:78435
TITLE:	Method and device for in-situ formulation of a medicinal solution for parenteral application
INVENTOR(S):	Kuehn, Bernd; Wiessmeier, Georg; Rupp, Roland; Krumbach, Bernd; Weismantel, Lothar; Herrmann, Erhard; Klein, Juergen
PATENT ASSIGNEE(S):	Bayer Aktiengesellschaft, Germany
SOURCE:	PCT Int. Appl., 47 pp.

Updated Search

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932175	A1	19990701	WO 1998-EP8014	19981209
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19757224	A1	19990701	DE 1997-19757224	19971222
AU 9922694	A1	19990712	AU 1999-22694	19981209
EP 1045709	A1	20001025	EP 1998-966273	19981209
EP 1045709	B1	20031203		
R: DE, ES, FR, GB, IT				
JP 2001526094	T2	20011218	JP 2000-525164	19981209
ES 2212390	T3	20040716	ES 1998-966273	19981209
US 6540715	B1	20030401	US 2000-582245	20000803

PRIORITY APPLN. INFO.:
DE 1997-19757224 A 19971222
WO 1998-EP8014 W 19981209

AB In the title method, ≥2 dosed partial flows are continually incorporated by a mixer into a total volume flow containing active substances to form a medicinal infusion solution which is not in thermodn. equilibrium; the resulting total volume flow after mixing is 0.2-500 mL/h, preferably 5-500 mL/h. One of the partial flows may be an active substance concentrate in an organic or aqueous-organic solvent, whereas the other partial flow comprises an aqueous or aqueous-organic diluent; the nonequil. state may comprise a supersatd. solution The mixer is preferably one free of dead space, such as an orifice-type blender. An active substance administration set comprises the mixer, infusion tubing, storage containers for the active substance concentrate and diluent, and packing materials. Thus, a 2% concentrate of oxazolidinone antibiotic Bay 17-1648 in glycofurol was delivered with a perfusion pump to a mixer for dilution 1:13 with water delivered with an infusion pump, to produce a total volume flow of 430 mL effluent/h containing 7% glycofurol and 140 mg Bay 17-1648/100 mL (.apprx.7 times the concentration for saturation); this solution was stable against crystallization of Bay 17-1648 for ≥1 min, and glycofurol at this concentration was well tolerated. Administration of a daily dose of 1000 mg Bay 17-1648 required an infusion volume of 717 mL, which would require .apprx.100 min for infusion.

IT 184157-64-0, Bay 17-1648
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method and device for in-situ formulation of medicinal solution for parenteral application)

RN 184157-64-0 HCAPLUS
CN Propanamide, N-[[(5S)-3-(2,3-dihydro-3-methyl-2-oxo-6-benzothiazolyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Updated Search

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 34 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:77555 HCAPLUS
DOCUMENT NUMBER: 130:139335
TITLE: Preparation of tricyclically substituted oxazolidinones as bactericides
INVENTOR(S): Bartel, Stephan; Guarnieri, Walter; Riedl, Bernd; Habich, Dieter; Stolle, Andreas; Ruppelt, Martin; Raddatz, Siegfried; Rosentreter, Ulrich; Wild, Hanno; Endermann, Rainer; Kroll, Hein-peter
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany; et al.
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9903846	A1	19990128	WO 1998-EP4252		19980708
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
DE 19730847	A1	19990128	DE 1997-19730847		19970718
AU 9884417	A1	19990210	AU 1998-84417		19980708
ZA 9806360	A	19990127	ZA 1998-6360		19980717
PRIORITY APPLN. INFO.:			DE 1997-19730847	A	19970718
			WO 1998-EP4252	W	19980708

OTHER SOURCE(S): MARPAT 130:139335
GI

Updated Search



I

Q =





II

AB Title compds. [I; R1= N3, OH, OMe, OSO2Me, NH2, NHCOCH3, etc.; E = O, S, CO, SO, SO2, NC2H5, etc.; A, A1, A2, A3 are independently CH, N, with no more than one N; L and M are independently H, OH, CO, CN, NO2, CHO, etc.; dotted bonds = one single bond to I and the other single bond to a H] are prepared as antibacterial medicaments. Thus, compound II was prepared from cycloaddn. of 2-benzyloxycarbonylaminofluorene and (R)-2,3-epoxypropyl butanoate in the presence of Bu lithium in hexane.

IT 220059-31-4P 220059-56-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tricyclically substituted oxazolidinones as bactericides)

RN 220059-31-4 HCAPLUS

CN Acetamide, N-[[(5S)-3-(2-dibenzothienyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220059-56-3 HCAPLUS

CN Acetamide, N-[[(5S)-2-oxo-3-[7-(3-pyridinyl)-9H-fluoren-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



IT 220058-98-0P 220059-01-8P 220059-05-2P
220059-07-4P 220059-08-5P 220059-09-6P
220059-12-1P 220059-13-2P 220059-16-5P
220059-17-6P 220059-18-7P 220059-19-8P
220059-25-6P 220059-26-7P 220059-29-0P
220059-33-6P 220059-34-7P 220059-35-8P
220059-36-9P 220059-37-0P 220059-38-1P
220059-39-2P 220059-42-7P 220059-43-8P
220059-46-1P 220059-47-2P 220059-50-7P
220059-51-8P 220059-55-2P 220059-59-6P
220059-60-9P 220059-61-0P 220059-62-1P
220059-64-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of tricyclically substituted oxazolidinones as bactericides)

RN 220058-98-0 HCAPLUS
CN Acetamide, N-[[(5S)-3-(9H-fluoren-2-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220059-01-8 HCAPLUS
CN Propanamide, N-[[(5S)-3-(9H-fluoren-2-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220059-05-2 HCAPLUS
CN Acetamide, N-[[(5S)-3-(9-ethyl-9H-carbazol-3-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Updated Search

Absolute stereochemistry.



RN 220059-07-4 HCAPLUS
CN Propanamide, N-[[(5S)-3-(9-ethyl-9H-carbazol-3-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220059-08-5 HCAPLUS
CN Acetamide, N-[[(5S)-3-(7-acetyl-9H-fluoren-2-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220059-09-6 HCAPLUS
CN Propanamide, N-[[(5S)-3-(7-acetyl-9H-fluoren-2-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 220059-12-1 HCAPLUS
CN Acetamide, N-[[(5S)-3-(3-dibenzofuranyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220059-13-2 HCAPLUS
CN Propanamide, N-[[(5S)-3-(3-dibenzofuranyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220059-16-5 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-[8-(1E)-1-pentenyl-3-dibenzofuranyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



Updated Search

RN 220059-17-6 HCAPLUS
CN Propanamide, N-[[(5S)-2-oxo-3-[8-(1E)-1-pentenyl-3-dibenzofuranyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 220059-18-7 HCAPLUS
CN Acetamide, N-[[(5S)-3-(8-acetyl-3-dibenzofuranyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220059-19-8 HCAPLUS
CN Propanamide, N-[[(5S)-3-(8-acetyl-3-dibenzofuranyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220059-25-6 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-(9-oxo-9H-fluoren-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 220059-26-7 HCAPLUS
CN Propanamide, N-[[(5S)-2-oxo-3-(9-oxo-9H-fluoren-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220059-29-0 HCAPLUS
CN Propanamide, N-[[(5S)-3-(2-dibenzothienyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220059-33-6 HCAPLUS
CN Acetamide, N-[[(5S)-3-(9H-carbazol-3-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

RN 220059-34-7 HCAPLUS
CN Acetamide, N-[[(5S)-3-[7-(dimethylamino)-9H-fluoren-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220059-35-8 HCAPLUS
CN Acetamide, N-[[(5S)-3-(7-cyano-9H-fluoren-2-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220059-36-9 HCAPLUS
CN Propanamide, N-[[(5S)-3-[7-(dimethylamino)-9H-fluoren-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220059-37-0 HCAPLUS
CN Acetamide, N-[[(5S)-3-(7-bromo-9H-fluoren-2-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

RN 220059-38-1 HCAPLUS
CN Propanamide, N-[[(5S)-3-(3-dibenzothienyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220059-39-2 HCAPLUS
CN Acetamide, N-[[(5S)-3-(3-dibenzothienyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220059-42-7 HCAPLUS
CN Acetamide, N-[[(5S)-3-(9-methyl-9H-carbazol-2-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220059-43-8 HCAPLUS
CN Propanamide, N-[[(5S)-3-(9-methyl-9H-carbazol-2-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 220059-46-1 HCAPLUS
CN Acetamide, N-[[(5S)-3-(5H-indeno[1,2-b]pyridin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220059-47-2 HCAPLUS
CN Propanamide, N-[[(5S)-3-(5H-indeno[1,2-b]pyridin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220059-50-7 HCAPLUS
CN Acetamide, N-[[(5S)-3-(5,5-dioxido-2-dibenzothienyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

RN 220059-51-8 HCAPLUS
CN Acetamide, N-[[(5S)-3-(5-oxido-2-dibenzothienyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220059-55-2 HCAPLUS
CN Propanamide, N-[[(5S)-2-oxo-3-[7-(3-pyridinyl)-9H-fluoren-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220059-59-6 HCAPLUS
CN Acetamide, N-[[(5S)-2-oxo-3-[7-(3-pyridinyl)-9H-fluoren-2-yl]-5-oxazolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220059-60-9 HCAPLUS
CN Acetamide, N-[[(5S)-3-(5,5-dioxido-3-dibenzothienyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 220059-61-0 HCAPLUS
CN Acetamide, N-[[(5S)-3-benzofuro[2,3-b]pyridin-7-yl-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220059-62-1 HCAPLUS
CN Acetamide, N-[[(5S)-3-benzofuro[3,2-c]pyridin-7-yl-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220059-64-3 HCAPLUS
CN Acetamide, N-[[(5S)-3-benzofuro[2,3-c]pyridin-7-yl-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 35 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:552637 HCAPLUS
DOCUMENT NUMBER: 127:149139

Updated Search

TITLE: Preparation of bactericidal pyridothienyl- and pyridofuryloxazolidinones

INVENTOR(S): Riedl, Bernd; Haebich, Dieter; Stolle, Andreas; Ruppelt, Martin; Bartel, Stefan; Guarnieri, Walter; Endermann, Rainer; Kroll, Hein-Peter

PATENT ASSIGNEE(S): Bayer A.-G., Germany

SOURCE: Ger. Offen., 28 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19601264	A1	19970717	DE 1996-19601264	19960116
EP 785200	A2	19970723	EP 1997-100025	19970103
EP 785200	A3	19990210		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AU 9710098	A1	19970724	AU 1997-10098	19970109
US 5827857	A	19981027	US 1997-781001	19970109
CA 2194938	AA	19970717	CA 1997-2194938	19970113
JP 09194482	A2	19970729	JP 1997-17559	19970114
NO 9700175	A	19970717	NO 1997-175	19970115
ZA 9700303	A	19970717	ZA 1997-303	19970115
CN 1161968	A	19971015	CN 1997-101806	19970116
BR 9700702	A	19980901	BR 1997-702	19970116

PRIORITY APPLN. INFO.: DE 1996-19601264 A 19960116

OTHER SOURCE(S): MARPAT 127:149139

GI



I



II

AB Title compds. I [R = pyridothienyl, pyridofuryl; R1 = N3, (un)substituted OH, NH2] were prepared Thus, 2-chloro-6-methylpyridine-3-carebonitrile was treated with HSCH2CO2Me to give Me 3-amino-6-methylthieno[2,3-b]pyridine-2-carboxylate, which was deaminated, and converted to the 2-butoxycarbonylamino derivative via the acid azide. 2-Butoxycarbonylamino-6-methylthieno[2,3-b]pyridine was cyclized with (R)-glycidyl butyrate to give the oxazolidinone II [R2 = OH]. This was converted to II [R2 = NHCSMe] which had min. inhibitory concns. against several staphylococcus strains of 2 μg/mL.

IT 193400-72-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of bactericidal pyridothienyl- and pyridofuryloxazolidinones)

RN 193400-72-5 HCAPLUS

CN Acetamide, N-[[3-(5-methylthieno[2,3-b]pyridin-2-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Updated Search

Absolute stereochemistry.



IT 193400-73-6P 193400-79-2P 193400-82-7P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of bactericidal pyridothienyl- and pyridofuryloxazolidinones)
RN 193400-73-6 HCAPLUS
CN Acetamide, N-[(2-oxo-3-thieno[2,3-b]pyridin-2-yl-5-oxazolidinyl)methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 193400-79-2 HCAPLUS
CN Propanamide, N-[[3-(6-methylthieno[2,3-b]pyridin-2-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 193400-82-7 HCAPLUS
CN Acetamide, N-[[3-(6-methylthieno[2,3-b]pyridin-2-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



L23 ANSWER 36 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:552636 HCAPLUS
DOCUMENT NUMBER: 127:149138
TITLE: Preparation of antimicrobial dihydroquinolinyloxazolidinones
INVENTOR(S): Haebich, Dieter; Stolle, Andreas; Riedl, Bernd; Ruppelt, Martin; Bartel, Stefan; Guarnieri, Walter; Endermann, Rainer; Kroll, Hein-Peter
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Ger. Offen., 29 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19601265	A1	19970717	DE 1996-19601265	19960116
EP 785197	A2	19970723	EP 1997-100026	19970103
EP 785197	A3	19990210		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
US 5861413	A	19990119	US 1997-781002	19970109
AU 711924	B2	19991021	AU 1997-10097	19970109
CA 2194945	AA	19970717	CA 1997-2194945	19970113
JP 09194478	A2	19970729	JP 1997-15889	19970113
NO 9700174	A	19970717	NO 1997-174	19970115
ZA 9700302	A	19970717	ZA 1997-302	19970115
BR 9700688	A	19980901	BR 1997-688	19970115
HU 9700126	A2	19981228	HU 1997-126	19970115
CN 1163892	A	19971105	CN 1997-102291	19970116

PRIORITY APPLN. INFO.: DE 1996-19601265 A 19960116
OTHER SOURCE(S): MARPAT 127:149138
GI



I

Updated Search

AB Title compds. were prepared Thus, 6-aminoquinoline was N-benzyloxycarbonylated and treated with (R)-glycidyl butyrate to give (5R)-3-(6-quinolinyl)-5-hydroxymethyl-2-oxazolidinone which was converted to the acetylaminomethyl deriv.in 4 steps and then to the dihydroquinoline via the N-oxide, followed by methylation to give the title compound I. I had min. inhibitory concns. against Staphylococcus 133 and Mycobacterium smegmatis of 2 μg/mL.

IT 193359-44-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of antimicrobial dihydroquinolinyloxazolidinones)

RN 193359-44-3 HCAPLUS

CN Acetamide, N-[[3-[1-(cyanomethyl)-1,2-dihydro-2-oxo-6-quinolinyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 193359-38-5P 193359-40-9P 193359-42-1P
193359-46-5P 193359-56-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of antimicrobial dihydroquinolinyloxazolidinones)

RN 193359-38-5 HCAPLUS

CN Acetamide, N-[[3-(1,2-dihydro-1-methyl-2-oxo-6-quinolinyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 193359-40-9 HCAPLUS

CN Acetamide, N-[[3-(1-ethyl-1,2-dihydro-2-oxo-6-quinolinyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Updated Search

Absolute stereochemistry.



RN 193359-42-1 HCAPLUS
CN Acetamide, N-[[3-[1,2-dihydro-1-(1-methylethyl)-2-oxo-6-quinolinyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 193359-46-5 HCAPLUS
CN Acetamide, N-[[3-[1,2-dihydro-1-(2-hydroxyethyl)-2-oxo-6-quinolinyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 193359-56-7 HCAPLUS
CN Acetamide, N-[[3-[1,2-dihydro-1-(methylsulfonyl)-2-oxo-6-quinolinyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



IT 175391-92-1P 175392-27-5P 193359-34-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of antimicrobial dihydroquinolinyloxazolidinones)
RN 175391-92-1 HCAPLUS
CN Acetamide, N-[[2-oxo-3-(6-quinolinyl)-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175392-27-5 HCAPLUS
CN Acetamide, N-[[3-(1-oxido-6-quinolinyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 193359-34-1 HCAPLUS
CN Acetamide, N-[[3-(1,2-dihydro-2-oxo-6-quinolinyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



IT 193359-48-7P 193359-50-1P 193359-52-3P
193359-55-6P 193359-58-9P 193359-61-4P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of antimicrobial dihydroquinolinyloxazolidinones)

RN 193359-48-7 HCAPLUS

CN Acetamide, N-[[3-[1,2-dihydro-2-oxo-1-(phenylmethyl)-6-quinolinyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 193359-50-1 HCAPLUS

CN 1(2H)-Quinolineacetamide, 6-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-oxo-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 193359-52-3 HCAPLUS

CN Acetamide, N-[[3-[1,2-dihydro-1-(hydroxymethyl)-2-oxo-6-quinolinyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 193359-55-6 HCAPLUS
CN Acetamide, N-[[3-[1-[(dimethylamino)methyl]-1,2-dihydro-2-oxo-6-quinolinyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 193359-58-9 HCAPLUS
CN Acetamide, N-[[3-[1-(3-chlorobenzoyl)-1,2-dihydro-2-oxo-6-quinolinyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 193359-61-4 HCAPLUS
CN 1(2H)-Quinolinecarboxamide, 6-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-N-methyl-N-[(methylamino)carbonyl]-2-oxo-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



L23 ANSWER 37 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:453982 HCAPLUS
DOCUMENT NUMBER: 127:81464
TITLE: Preparation of oxazolidinone antibacterial agents with tricyclic substituents
INVENTOR(S): Thomas, Richard C.; Cleek, Gary J.; Hutchinson, Douglas K.; Yamada, Hiroyoshi
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9719089	A1	19970529	WO 1996-US17120	19961105
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9608661	A	19980414	ZA 1996-8661	19961014
AU 9676651	A1	19970611	AU 1996-76651	19961105
EP 874852	A1	19981104	EP 1996-939496	19961105
EP 874852	B1	20040331		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2000500489	T2	20000118	JP 1997-519726	19961105
AT 263172	E	20040415	AT 1996-939496	19961105
PT 874852	T	20040831	PT 1996-939496	19961105
ES 2217329	T3	20041101	ES 1996-939496	19961105
TW 426683	B	20010321	TW 1996-85114048	19961115
US 5922707	A	19990713	US 1997-850424	19970502
US 5955460	A	19990921	US 1999-250382	19990215
PRIORITY APPLN. INFO.:			US 1995-7371P	P 19951117
			US 1996-744519	B1 19961105
			WO 1996-US17120	W 19961105
			US 1997-850424	A3 19970502

OTHER SOURCE(S): MARPAT 127:81464

Updated Search

GI



I

AB The title compds. [I; R = H, alkyl, cycloalkyl, alkoxy, (un)substituted NH2; X = (un)substituted NH, (un)substituted CH2, S, SO, SO2, O; Y = H, halogen; Z = (un)substituted NH, S, SO, SO2, O], which are effective antibiotics against a number of gram-pos. aerobic bacteria as well as anaerobic organisms and acid-fast organisms, are prepared Thus, phenylmethyl 8-[5-(S)-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4a,5-tetrahydropyrazino[2,1-c][1,4]benzoxazine-3(4H)-carboxylate was prepared in 9 steps from 2-pyrazinecarboxylic acid and demonstrated a MIC against S. aureus UC Number 9213 of 8 μg/mL.

IT 191738-68-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of oxazolidinone antibacterial agents with tricyclic substituents)

RN 191738-68-8 HCAPLUS

CN Pyrazino[2,1-c][1,4]benzoxazine-3(4H)-carboxylic acid, 8-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4a,5-tetrahydro-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 191738-72-4P 191738-76-8P 191738-81-5P
191738-85-9P 191738-89-3P 191738-94-0P
191738-96-2P 191738-98-4P 191739-01-2P
191739-03-4P 191739-05-6P 191739-07-8P
191739-09-0P 191739-11-4P 191739-13-6P
191739-15-8P 191739-17-0P 191739-19-2P
191739-21-6P 191739-23-8P 191739-25-0P

Updated Search

191739-27-2P 191739-29-4P 191739-31-8P
191739-33-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolidinone antibacterial agents with tricyclic substituents)

RN 191738-72-4 HCAPLUS
CN Acetamide, N-[[3-[1,2,3,4,4a,5-hexahydro-3-[(phenylmethoxy)acetyl]pyrazino[2,1-c][1,4]benzoxazin-8-yl]-2-oxo-5-oxazolidinyl]methyl]-, [8(S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191738-76-8 HCAPLUS
CN Pyrazino[2,1-c][1,4]benzoxazine-3(4H)-carboxylic acid, 8-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4a,5-tetrahydro-, methyl ester, [8(S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191738-81-5 HCAPLUS
CN Acetamide, N-[[3-[1,2,3,4,4a,5-hexahydro-3-(hydroxyacetyl)pyrazino[2,1-c][1,4]benzoxazin-8-yl]-2-oxo-5-oxazolidinyl]methyl]-, [8(S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 191738-85-9 HCAPLUS
CN Acetamide, N-[[3-[1,2,3,4,4a,5-hexahydro-3-(5-isoxazolylcarbonyl)pyrazino[2,1-c][1,4]benzoxazin-8-yl]-2-oxo-5-oxazolidinyl]methyl]-, [8(S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191738-89-3 HCAPLUS
CN Acetamide, N-[[3-[1,2,3,4,4a,5-hexahydro-3-(1H-indol-2-ylcarbonyl)pyrazino[2,1-c][1,4]benzoxazin-8-yl]-2-oxo-5-oxazolidinyl]methyl]-, [8(S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191738-94-0 HCAPLUS
CN Pyrazino[2,1-c][1,4]benzoxazine-3(4H)-carboxylic acid,

Updated Search

8-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4a,5-tetrahydro-, phenylmethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191738-96-2 HCAPLUS
CN Pyrazino[2,1-c][1,4]benzoxazine-3(4H)-carboxylic acid, 8-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4a,5-tetrahydro-, phenylmethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191738-98-4 HCAPLUS
CN Pyrazino[2,1-c][1,4]benzoxazine-3(4H)-carboxylic acid, 8-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4a,5-tetrahydro-, methyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 191739-01-2 HCAPLUS
CN Pyrazino[2,1-c][1,4]benzoxazine-3(4H)-carboxylic acid, 8-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4a,5-tetrahydro-, methyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191739-03-4 HCAPLUS
CN Acetamide, N-[[3-(1,2,3,4,4a,5-hexahydropyrazino[2,1-c][1,4]benzoxazin-8-yl)-2-oxo-5-oxazolidinyl]methyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191739-05-6 HCAPLUS
CN Acetamide, N-[[3-(1,2,3,4,4a,5-hexahydropyrazino[2,1-c][1,4]benzoxazin-8-yl)-2-oxo-5-oxazolidinyl]methyl]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 191739-07-8 HCAPLUS
CN Acetamide, N-[[3-(1,2,3,4,4a,5-hexahydropyrazino[2,1-c][1,4]benzoxazin-8-yl)-2-oxo-5-oxazolidinyl]methyl]-, [8(S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191739-09-0 HCAPLUS
CN Acetamide, N-[[3-[3-(2-fluoroethyl)-1,2,3,4,4a,5-hexahydropyrazino[2,1-c][1,4]benzoxazin-8-yl]-2-oxo-5-oxazolidinyl]methyl]-, [8(S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191739-11-4 HCAPLUS
CN Acetamide, N-[[3-[3-(cyanomethyl)-1,2,3,4,4a,5-hexahydropyrazino[2,1-c][1,4]benzoxazin-8-yl]-2-oxo-5-oxazolidinyl]methyl]-, [8(S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 191739-13-6 HCAPLUS
CN Acetamide, N-[[3-[1,2,3,4,4a,5-hexahydro-3-(methylsulfonyl)pyrazino[2,1-c][1,4]benzoxazin-8-yl]-2-oxo-5-oxazolidinyl]methyl]-, [8(S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191739-15-8 HCAPLUS
CN Acetamide, N-[[3-(3-formyl-1,2,3,4,4a,5-hexahydropyrazino[2,1-c][1,4]benzoxazin-8-yl)-2-oxo-5-oxazolidinyl]methyl]-, [8(S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191739-17-0 HCAPLUS
CN Acetamide, N-[[3-(3-acetyl-1,2,3,4,4a,5-hexahydropyrazino[2,1-c][1,4]benzoxazin-8-yl)-2-oxo-5-oxazolidinyl]methyl]-, [8(S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 191739-19-2 HCAPLUS
CN Acetamide, N-[[3-[1,2,3,4,4a,5-hexahydro-3-(methoxyacetyl)pyrazino[2,1-c][1,4]benzoxazin-8-yl]-2-oxo-5-oxazolidinyl]methyl]-, [8(S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191739-21-6 HCAPLUS
CN Acetamide, N-[[3-[3-[(acetyloxy)acetyl]-1,2,3,4,4a,5-hexahydropyrazino[2,1-c][1,4]benzoxazin-8-yl]-2-oxo-5-oxazolidinyl]methyl]-, [8(S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191739-23-8 HCAPLUS
CN Acetamide, N-[[3-[3-(dichloroacetyl)-1,2,3,4,4a,5-hexahydropyrazino[2,1-c][1,4]benzoxazin-8-yl]-2-oxo-5-oxazolidinyl]methyl]-, [8(S)]- (9CI) (CA INDEX NAME)

Updated Search

Absolute stereochemistry.



RN 191739-25-0 HCAPLUS
CN Pyrazino[2,1-c][1,4]benzoxazine-3(4H)-carboxylic acid, 8-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4a,5-tetrahydro-, 1,1-dimethylethyl ester, [8(S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191739-27-2 HCAPLUS
CN Acetamide, N-[[3-[1,2,3,4,4a,5-hexahydro-3-(3-hydroxy-1-oxopropyl)pyrazino[2,1-c][1,4]benzoxazin-8-yl]-2-oxo-5-oxazolidinyl]methyl]-, [8(S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

RN 191739-29-4 HCAPLUS
CN Acetamide, N-[[3-[1,2,3,4,4a,5-hexahydro-3-(3-methoxy-1-oxopropyl)pyrazino[2,1-c][1,4]benzoxazin-8-yl]-2-oxo-5-oxazolidinyl]methyl]-, [8(S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191739-31-8 HCAPLUS
CN Acetamide, N-[[3-[3-(1,4-dioxopentyl)-1,2,3,4,4a,5-hexahydropyrazino[2,1-c][1,4]benzoxazin-8-yl]-2-oxo-5-oxazolidinyl]methyl]-, [8(S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191739-33-0 HCAPLUS
CN Acetamide, N-[[3-[1,2,3,4,4a,5-hexahydro-3-(5-nitro-2-thiazolyl)pyrazino[2,1-c][1,4]benzoxazin-8-yl]-2-oxo-5-oxazolidinyl]methyl]-, [8(S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



L23 ANSWER 38 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:753781 HCAPLUS
DOCUMENT NUMBER: 126:18862
TITLE: Preparation of N-(oxobenzoxazol-6-yl)oxazolidinones and analogs as antibacterial agents
INVENTOR(S): Stolle, Andreas; Haebich, Dieter; Bartel, Stephan; Riedl, Bernd; Ruppelt, Martin; Wild, Hanno; Endermann, Rainer; Bremm, Klaus-Dieter; Kroll, Hein-Peter; et al.
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Eur. Pat. Appl., 117 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 738726	A1	19961023	EP 1996-105539	19960409
EP 738726	B1	20010926		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
DE 19544106	A1	19961024	DE 1995-19544106	19951127
AT 206120	E	20011015	AT 1996-105539	19960409
ES 2164182	T3	20020216	ES 1996-105539	19960409
US 6069160	A	20000530	US 1996-631516	19960412
JP 08301869	A2	19961119	JP 1996-117117	19960416
AU 9650735	A1	19961031	AU 1996-50735	19960417
AU 705071	B2	19990513		
HU 9601001	A2	19980428	HU 1996-1001	19960417
CA 2174473	AA	19961022	CA 1996-2174473	19960418
NO 9601559	A	19961022	NO 1996-1559	19960419
ZA 9603138	A	19961104	ZA 1996-3138	19960419
CN 1138582	A	19961225	CN 1996-106152	19960419
BR 9602016	A	19980407	BR 1996-2016	19960422
CN 1161336	A	19971008	CN 1997-102064	19970118
PRIORITY APPLN. INFO.:			DE 1995-19514769 A	19950421
			DE 1995-19544106 A	19951127

OTHER SOURCE(S): MARPAT 126:18862
GI

Updated Search



II

AB Title compds. [I; R = e.g., oxobenzoxazol-6-yl, etc.; R1 = N3, (protected)hydroxy, acyloxy, alkylsulfonyloxy, NR4R5, etc.; R4,R5 = H, alkyl, Ph, etc.] were prepared Thus, 6-benzyloxycarbonylamino-3-methyl-2-benzothiazolinone (preparation given) was cyclocondensed with (R)-glycidyl butyrate to give title compound II. Data for antibacterial activity of selected I were given.

IT 184156-99-8P 184157-00-4P 184157-01-5P
184157-02-6P 184157-03-7P 184157-06-0P
184157-08-2P 184157-10-6P 184157-12-8P
184157-14-0P 184157-17-3P 184157-19-5P
184157-21-9P 184157-23-1P 184157-26-4P
184157-29-7P 184157-32-2P 184157-35-5P
184157-38-8P 184157-41-3P 184157-44-6P
184157-45-7P 184157-47-9P 184157-49-1P
184157-50-4P 184157-51-5P 184157-52-6P
184157-53-7P 184157-54-8P 184157-55-9P
184157-56-0P 184157-57-1P 184157-58-2P
184157-59-3P 184157-60-6P 184157-61-7P
184157-64-0P 184157-88-8P 184157-89-9P
184157-90-2P 184157-91-3P 184157-92-4P
184157-93-5P 184157-94-6P 184157-95-7P
184157-96-8P 184157-97-9P 184157-98-0P
184157-99-1P 184158-00-7P 184158-01-8P
184158-02-9P 184158-03-0P 184158-04-1P
184158-05-2P 184158-06-3P 184158-07-4P
184158-08-5P 184158-09-6P 184158-23-4P
184158-29-0P 184158-31-4P 184158-39-2P
184158-54-1P 184158-56-3P 184158-58-5P
184158-60-9P 184158-66-5P 184158-67-6P
184158-68-7P 184158-69-8P 184158-70-1P
184158-71-2P 184158-72-3P 184158-73-4P
184158-78-9P 184158-79-0P 184158-80-3P
184158-81-4P 184158-82-5P 184158-83-6P
184158-86-9P 184158-87-0P 184158-88-1P
184377-51-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(oxobenzoxazol-6-yl)oxazolidinones and analogs as antibacterial agents)

RN 184156-99-8 HCAPLUS

CN Acetamide, N-[[3-(2,3-dihydro-3-methyl-2-oxo-6-benzothiazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 184157-00-4 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-1,3-dimethyl-2-oxo-1H-benzimidazol-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184157-01-5 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-3-methyl-1-(3-methylbutyl)-2-oxo-1H-benzimidazol-5-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184157-02-6 HCAPLUS
CN Acetamide, N-[[3-[1-ethyl-2,3-dihydro-2-oxo-3-(phenylmethyl)-1H-benzimidazol-5-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

RN 184157-03-7 HCAPLUS
CN Acetamide, N-[[3-(3-ethyl-2,3-dihydro-2-oxo-6-benzothiazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184157-06-0 HCAPLUS
CN Acetamide, N-[[3-(1-ethyl-2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184157-08-2 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-2-oxo-6-benzoxazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 184157-10-6 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-2-oxo-5-benzoxazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



Updated Search

RN 184157-12-8 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-2-thioxo-6-benzoxazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 184157-14-0 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-2-thioxo-5-benzoxazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184157-17-3 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-2-thioxo-6-benzothiazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184157-19-5 HCAPLUS
CN Acetamide, N-[[3-(2-amino-6-benzoxazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184157-21-9 HCAPLUS

Updated Search

CN Acetamide, N-[[3-(2-amino-5-benzoxazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184157-23-1 HCAPLUS
CN Acetamide, N-[[3-(2-amino-6-benzoxazolyl)-2-oxo-5-oxazolidinyl]methyl]-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 184157-26-4 HCAPLUS
CN Acetamide, N-[[3-(2-amino-5-benzoxazolyl)-2-oxo-5-oxazolidinyl]methyl]-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 184157-29-7 HCAPLUS
CN Acetamide, N-[[3-(3-acetyl-2,3-dihydro-2-oxo-6-benzoxazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 184157-32-2 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-3-(methylsulfonyl)-2-oxo-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 184157-35-5 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-2-oxo-3-[(phenylmethoxy)acetyl]-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 184157-38-8 HCAPLUS
CN Acetamide, N-[[3-[3-(cyclopropylcarbonyl)-2,3-dihydro-2-oxo-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Updated Search



RN 184157-41-3 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-3-methyl-2-oxo-6-benzoxazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 184157-44-6 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-2-oxo-3-(phenylmethyl)-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 184157-45-7 HCAPLUS
CN 3(2H)-Benzoxazoleacetic acid, 6-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-oxo-, ethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 184157-47-9 HCAPLUS
CN Acetamide, N-[[3-[3-(cyanomethyl)-2,3-dihydro-2-oxo-6-benzoxazolyl]-2-oxo-

Updated Search

5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 184157-49-1 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-2-oxo-3-(2,2,2-trifluoroethyl)-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184157-50-4 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-3-(hydroxymethyl)-2-oxo-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 184157-51-5 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-3-methyl-2-thioxo-6-benzoxazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184157-52-6 HCAPLUS
CN Acetamide, N-[[3-(3-ethyl-2,3-dihydro-2-thioxo-6-benzoxazolyl)-2-oxo-5-

Updated Search

oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184157-53-7 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-3-propyl-2-thioxo-6-benzoxazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184157-54-8 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-3-methyl-2-thioxo-6-benzothiazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184157-55-9 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-3-(1-methylethyl)-2-oxo-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

RN 184157-56-0 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-3-(1-methylpropyl)-2-oxo-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (5S)-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184157-57-1 HCAPLUS
CN Acetamide, N-[[3-[3-(1-ethylpropyl)-2,3-dihydro-2-oxo-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184157-58-2 HCAPLUS
CN Acetamide, N-[[3-(3-cyclopropyl-2,3-dihydro-2-oxo-6-benzoxazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184157-59-3 HCAPLUS
CN Acetamide, N-[[3-(3-cyclobutyl-2,3-dihydro-2-oxo-6-benzoxazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 184157-60-6 HCAPLUS
CN Acetamide, N-[[3-(3-cyclopentyl-2,3-dihydro-2-oxo-6-benzoxazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184157-61-7 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184157-64-0 HCAPLUS
CN Propanamide, N-[[(5S)-3-(2,3-dihydro-3-methyl-2-oxo-6-benzothiazolyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

RN 184157-88-8 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-2-oxo-3-(2-propenyl)-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184157-89-9 HCAPLUS
CN Acetamide, N-[[3-(3-ethyl-2,3-dihydro-2-oxo-6-benzoxazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184157-90-2 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-2-oxo-3-propyl-6-benzoxazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184157-91-3 HCAPLUS
CN Acetamide, N-[[3-(3-butyl-2,3-dihydro-2-oxo-6-benzoxazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 184157-92-4 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-2-oxo-3-pentyl-6-benzoxazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184157-93-5 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-3-(2-methylpropyl)-2-oxo-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184157-94-6 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-3-(2-hydroxyethyl)-2-oxo-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184157-95-7 HCAPLUS
CN Acetamide, N-[[3-[3-[(dimethylamino)methyl]-2,3-dihydro-2-oxo-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Updated Search

Absolute stereochemistry.



RN 184157-96-8 HCAPLUS
CN Acetamide, N-[[3-[3-[(dimethylamino)methyl]-2,3-dihydro-2-oxo-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, hydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● x HCl

RN 184157-97-9 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-2-oxo-6-benzothiazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184157-98-0 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-3-(hydroxymethyl)-2-oxo-6-benzothiazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

RN 184157-99-1 HCAPLUS
CN Acetamide, N-[[3-[3-(fluoromethyl)-2,3-dihydro-2-oxo-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184158-00-7 HCAPLUS
CN Acetamide, N-[[3-[3-(fluoromethyl)-2,3-dihydro-2-oxo-6-benzothiazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184158-01-8 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-3-methyl-2-(2-propenylimino)-6-benzothiazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 184158-02-9 HCAPLUS
CN Cyclopropanecarboxamide, N-[6-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-3-methyl-2(3H)-benzothiazolylidene]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

Updated Search



RN 184158-03-0 HCAPLUS
CN Propanamide, N-[6-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-3-methyl-2(3H)-benzothiazolylidene]-2,2-dimethyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 184158-04-1 HCAPLUS
CN Acetamide, N-[6-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-3-methyl-2(3H)-benzothiazolylidene]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 184158-05-2 HCAPLUS
CN Acetamide, N-[6-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-3-methyl-2(3H)-benzothiazolylidene]-2,2,2-trichloro-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



Updated Search

RN 184158-06-3 HCAPLUS
CN Carbamic acid, [6-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-3-methyl-2(3H)-benzothiazolylidene]-, phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 184158-07-4 HCAPLUS
CN Carbamic acid, [6-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-3-methyl-2(3H)-benzothiazolylidene]-, 4-nitrophenyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 184158-08-5 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-3-methyl-2-[[(methylamino)carbonyl]imino]-6-benzothiazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 184158-09-6 HCAPLUS
CN Acetamide, N-[[3-[2-(cyanoimino)-2,3-dihydro-3-methyl-6-benzothiazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

Updated Search



RN 184158-23-4 HCAPLUS
CN Propanamide, N-[[3-(3-ethyl-2,3-dihydro-2-oxo-6-benzothiazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184158-29-0 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-3-(1-methylethyl)-2-oxo-6-benzothiazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184158-31-4 HCAPLUS
CN Propanamide, N-[[3-[2,3-dihydro-3-(1-methylethyl)-2-oxo-6-benzothiazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

RN 184158-39-2 HCAPLUS
CN Propanamide, N-[[3-[2,3-dihydro-3-(1-methylethyl)-2-oxo-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184158-54-1 HCAPLUS
CN Acetamide, N-[[3-[3-(2-chloro-1-methylethyl)-2,3-dihydro-2-oxo-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (5S)-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184158-56-3 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-2-oxo-3-[1-(phenylmethyl)-3-pyrrolidinyl]-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (5S)-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184158-58-5 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-2-oxo-3-[1-(phenylmethyl)-4-piperidinyl]-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 184158-60-9 HCAPLUS
CN Propanamide, N-[[3-(2,3-dihydro-2-oxo-6-benzoxazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184158-66-5 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-2-oxo-3-(4-pyridinylmethyl)-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184158-67-6 HCAPLUS
CN Propanamide, N-[[3-(2,3-dihydro-3-methyl-2-oxo-6-benzoxazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 184158-68-7 HCAPLUS
CN Propanamide, N-[[3-(3-ethyl-2,3-dihydro-2-oxo-6-benzoxazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184158-69-8 HCAPLUS
CN Propanamide, N-[[3-(2,3-dihydro-2-oxo-3-propyl-6-benzoxazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184158-70-1 HCAPLUS
CN Propanamide, N-[[3-[2,3-dihydro-3-(2-methylpropyl)-2-oxo-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 184158-71-2 HCAPLUS
CN 3(2H)-Benzoxazoleacetic acid, 2-oxo-6-[2-oxo-5-[[(1-oxopropyl)amino]methyl]-3-oxazolidinyl]-, phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184158-72-3 HCAPLUS
CN Propanamide, N-[[3-[3-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-2,3-dihydro-2-oxo-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184158-73-4 HCAPLUS
CN Propanamide, N-[[3-[3-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-2,3-dihydro-2-oxo-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 184158-78-9 HCAPLUS
CN Acetamide, N-[[3-[3-(2-azido-1-methylethyl)-2,3-dihydro-2-oxo-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (5S)-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184158-79-0 HCAPLUS
CN Propanamide, N-[[3-[3-(3-aminopropyl)-2,3-dihydro-2-oxo-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184158-80-3 HCAPLUS
CN Propanamide, N-[[3-[3-(2-aminoethyl)-2,3-dihydro-2-oxo-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 184158-81-4 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-2-oxo-3-(4-piperidinyl)-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184158-82-5 HCAPLUS
CN 3(2H)-Benzoxazoleacetic acid, 6-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-oxo-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184158-83-6 HCAPLUS
CN Acetamide, N-[[3-[3-(2-amino-1-methylethyl)-2,3-dihydro-2-oxo-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (5S)-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 184158-86-9 HCAPLUS
CN Propanamide, N-[[3-[3-(3-aminopropyl)-2,3-dihydro-2-oxo-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, hydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 184158-87-0 HCAPLUS
CN Propanamide, N-[[3-[2,3-dihydro-2-oxo-3-(4-pyridinylmethyl)-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, hydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 184158-88-1 HCAPLUS
CN Propanamide, N-[[3-[2,3-dihydro-3-[(5-nitro-2-pyridinyl)methyl]-2-oxo-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, hydrochloride, (S)- (9CI) (CA INDEX NAME)

Updated Search

Absolute stereochemistry.



●x HCl

RN 184377-51-3 HCAPLUS
CN Acetamide, N-[[3-[3-(2-amino-1-methylethyl)-2,3-dihydro-2-oxo-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, hydrochloride, (5S)-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

IT 176490-94-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-(oxobenzoxazol-6-yl)oxazolidinones and analogs as antibacterial agents)
RN 176490-94-1 HCAPLUS
CN Acetamide, N-[[2-oxo-3-[2-[(phenylmethyl)thio]-6-benzothiazolyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

IT 176490-91-8P 176491-09-1P 184159-05-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-(oxobenzoxazol-6-yl)oxazolidinones and analogs as antibacterial agents)
RN 176490-91-8 HCAPLUS
CN Acetamide, N-[[3-[2-(methylthio)-6-benzothiazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-09-1 HCAPLUS
CN Benzothiazolium, 6-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-3-methyl-2-(methylthio)-, iodide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● I^-

RN 184159-05-5 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-2-imino-3-methyl-6-benzoxazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L23 ANSWER 39 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:294873 HCAPLUS
DOCUMENT NUMBER: 124:343286

Updated Search

TITLE: Preparation of (benzoxazolyl)- and (benzothiazolyl)oxazolidinone antibiotics

INVENTOR(S): Haebisch, Dieter; Riedl, Bernd; Ruppelt, Martin; Stolle, Andreas; Wild, Hanno; Endermann, Rainer; Bremm, Klaus-Dieter; Kroll, Hein-Peter; Labischinski, Harald; et al.

PATENT ASSIGNEE(S): Bayer A.-G., Germany

SOURCE: Ger. Offen., 71 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19514313	A1	19960208	DE 1995-19514313	19950418
RO 115263	B1	19991230	RO 1995-1322	19950718
EP 697412	A1	19960221	EP 1995-111477	19950721
EP 697412	B1	20000112		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 188698	E	20000115	AT 1995-111477	19950721
AU 9527230	A1	19960215	AU 1995-27230	19950727
AU 698939	B2	19981112		
US 5529998	A	19960625	US 1995-508245	19950727
JP 08081463	A2	19960326	JP 1995-211265	19950728
CA 2155092	AA	19960204	CA 1995-2155092	19950731
IL 114784	A1	19991028	IL 1995-114784	19950731
FI 9503665	A	19960204	FI 1995-3665	19950801
NO 9503045	A	19960205	NO 1995-3045	19950802
ZA 9506445	A	19960322	ZA 1995-6445	19950802
HU 75037	A2	19970328	HU 1995-2295	19950802
CN 1122803	A	19960522	CN 1995-115330	19950803

PRIORITY APPLN. INFO.: DE 1994-4427475 A1 19940803
DE 1995-19514313 A 19950418

OTHER SOURCE(S): MARPAT 124:343286

GI



I



II

Updated Search

AB The title compds. [I; A = O, S(O)a; a = 0, 2; G, L, M = H, CO2H, halogen, CN, CHO, CF3, NO2, (un)branched alkoxy, etc.; R1 = OSO2R3, tertiary-amino group; R3 = (un)substituted alkyl, (un)substituted Ph; R2 = H, CHO, CO2H, alkoxycarbonyl, etc.; * = chiral C], useful in pharmaceuticals, especially as antibiotics, are prepared Thus, benzothiazole II, m.p. 228°, was prepared by the m-chloroperbenzoic acid oxidation of the methylthio analog, and demonstrated a MIC against Staph. 133 (sic) of 1 μg/mL and Staph. 48N (sic) of 2 mg/mL.

IT 176490-91-8P 176490-92-9P 176490-93-0P
176490-94-1P 176490-95-2P 176490-96-3P
176490-97-4P 176490-98-5P 176490-99-6P
176491-00-2P 176491-01-3P 176491-02-4P
176491-03-5P 176491-04-6P 176491-05-7P
176491-06-8P 176491-07-9P 176491-08-0P
176491-09-1P 176491-13-7P 176491-14-8P
176491-15-9P 176491-24-0P 176491-25-1P
176491-26-2P 176491-27-3P 176491-28-4P
176491-29-5P 176491-30-8P 176491-31-9P
176491-32-0P 176491-33-1P 176491-34-2P
176491-35-3P 176491-36-4P 176491-37-5P
176491-38-6P 176491-39-7P 176491-40-0P
176491-41-1P 176491-42-2P 176491-43-3P
176491-44-4P 176491-45-5P 176491-46-6P
176491-47-7P 176491-48-8P 176491-49-9P
176491-50-2P 176491-51-3P 176491-52-4P
176491-53-5P 176491-54-6P 176491-55-7P
176491-56-8P 176491-57-9P 176491-58-0P
176491-59-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (benzoxazolyl)- and (benzothiazolyl)oxazolidinone antibiotics)

RN 176490-91-8 HCAPLUS
CN Acetamide, N-[[3-[2-(methylthio)-6-benzothiazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176490-92-9 HCAPLUS
CN Acetamide, N-[[3-(2-methyl-6-benzoxazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

RN 176490-93-0 HCAPLUS
CN Acetamide, N-[[3-(2-methyl-6-benzothiazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176490-94-1 HCAPLUS
CN Acetamide, N-[[2-oxo-3-[2-[(phenylmethyl)thio]-6-benzothiazolyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176490-95-2 HCAPLUS
CN Acetamide, N-[[2-oxo-3-[2-(2-phenylethenyl)-6-benzothiazolyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 176490-96-3 HCAPLUS
CN Acetamide, N-[[2-oxo-3-(2-phenyl-5-benzoxazolyl)-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

RN 176490-97-4 HCAPLUS
CN Acetamide, N-[[3-(2-methyl-5-benzothiazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176490-98-5 HCAPLUS
CN Benzothiazolium, 6-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,3-dimethyl-, iodide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176490-99-6 HCAPLUS
CN Acetamide, N-[[3-[2-(methylsulfinyl)-6-benzothiazolyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 176491-00-2 HCAPLUS
CN Acetamide, N-[[2-oxo-3-[2-[(phenylmethyl)sulfonyl]-6-benzothiazolyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 176491-01-3 HCAPLUS
CN Acetamide, N-[[3-[2-(cyclopropylamino)-6-benzothiazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-02-4 HCAPLUS
CN Acetamide, N-[[2-oxo-3-[2-(2-pyridinylthio)-6-benzothiazolyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-03-5 HCAPLUS
CN Acetamide, N-[[2-oxo-3-[2-[(phenylmethyl)sulfinyl]-6-benzothiazolyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 176491-04-6 HCAPLUS
CN Acetamide, N-[[3-[2-(methylsulfonyl)-6-benzothiazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 176491-05-7 HCAPLUS
CN Acetamide, N-[[2-oxo-3-[2-(2-pyrimidinylthio)-6-benzothiazolyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-06-8 HCAPLUS
CN Acetamide, N-[[3-[2-(chloromethyl)-6-benzothiazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-07-9 HCAPLUS
CN Acetamide, N-[[3-(2-formyl-6-benzothiazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-08-0 HCAPLUS
CN Acetamide, N-[[3-[2-(hydroxymethyl)-6-benzothiazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 176491-09-1 HCAPLUS
CN Benzothiazolium, 6-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-3-methyl-2-(methylthio)-, iodide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● I^-

RN 176491-13-7 HCAPLUS
CN Acetamide, N-[[3-[2-[2-(4-chlorophenyl)ethenyl]-6-benzothiazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 176491-14-8 HCAPLUS
CN Acetamide, N-[[3-[2-(3-butenyl)-5-benzothiazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

RN 176491-15-9 HCAPLUS
CN Carbonothioic acid, S-[6-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-benzothiazolyl] O-ethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-24-0 HCAPLUS
CN Acetamide, N-[[3-(6-benzoxazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-25-1 HCAPLUS
CN Acetamide, N-[[3-[2-[4-(4-methoxyphenyl)-1-piperazinyl]-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-26-2 HCAPLUS
CN Acetamide, N-[[2-oxo-3-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]-6-benzoxazolyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 176491-27-3 HCAPLUS
CN Acetamide, N-[[2-oxo-3-[2-[4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]-6-benzoxazolyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-28-4 HCAPLUS
CN Acetamide, N-[[3-[2-[4-[2-(4-morpholinyl)-2-oxoethyl]-1-piperazinyl]-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-29-5 HCAPLUS
CN Acetamide, N-[[3-[2-[4-(2-methoxyethyl)-1-piperazinyl]-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Updated Search

Absolute stereochemistry.



RN 176491-30-8 HCAPLUS
CN Acetamide, N-[[3-[2-(hexahydro-1H-1,4-diazepin-1-yl)-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-31-9 HCAPLUS
CN Acetamide, N-[[3-[2-[[2-(4-methoxyphenyl)ethyl]amino]-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-32-0 HCAPLUS
CN Acetamide, N-[[2-oxo-3-[2-[[[4-(trifluoromethyl)phenyl]methyl]amino]-6-benzoxazolyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

RN 176491-33-1 HCAPLUS
CN 3-Piperidinecarboxamide, 1-[6-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-benzoxazolyl]- (9CI) (CA INDEX NAME)



RN 176491-34-2 HCAPLUS
CN Pyridinium, 1-[6-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-benzoxazolyl]-4-(dimethylamino)-, iodide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-35-3 HCAPLUS
CN Acetamide, N-[[2-oxo-3-[2-(2-pyridinyloxy)-6-benzoxazolyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-36-4 HCAPLUS
CN Acetamide, N-[[3-[2-[(2-hydroxyethyl)amino]-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 176491-37-5 HCAPLUS
CN Acetamide, N-[[3-[2-[(3-hydroxypropyl)amino]-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-38-6 HCAPLUS
CN Acetamide, N-[[3-[2-[[2-(2-hydroxyethoxy)ethyl]amino]-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-39-7 HCAPLUS
CN Acetamide, N-[[3-[2-[3-(2-hydroxyethyl)-1-imidazolidinyl]-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-40-0 HCAPLUS
CN Acetamide, N-[[3-[2-[(2-hydroxypropyl)amino]-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Updated Search



RN 176491-41-1 HCAPLUS
CN Acetamide, N-[[3-[2-[(2-hydroxy-1,1-dimethylethyl)amino]-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-42-2 HCAPLUS
CN Acetamide, N-[[2-oxo-3-[2-[4-(2-pyridinyl)-1-piperazinyl]-6-benzoxazolyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-43-3 HCAPLUS
CN Acetamide, N-[[3-[2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 176491-44-4 HCAPLUS
CN Acetamide, N-[[3-[2-[4-[2-(4-morpholinyl)ethyl]-1-piperazinyl]-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-45-5 HCAPLUS
CN Acetamide, N-[[2-oxo-3-[2-(4-pyrazinyl-1-piperazinyl)-6-benzoxazolyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-46-6 HCAPLUS
CN Acetamide, N-[[3-[2-[4-(4-nitrophenyl)-1-piperazinyl]-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 176491-47-7 HCAPLUS
CN Acetamide, N-[[3-[2-(cyclopropylmethoxy)-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-48-8 HCAPLUS
CN Acetamide, N-[[3-[2-[4-[2-(dimethylamino)ethyl]-1-piperazinyl]-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-49-9 HCAPLUS
CN Acetamide, N-[[3-[2-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

RN 176491-50-2 HCAPLUS
CN Acetamide, N-[[3-[2-(4-hydroxy-1-piperidinyl)-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-51-3 HCAPLUS
CN Acetamide, N-[[2-oxo-3-[2-[[3-(1-piperidinyl)propyl]amino]-6-benzoxazolyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-52-4 HCAPLUS
CN Acetamide, N-[[3-[2-[(1,3-benzodioxol-5-ylmethyl)amino]-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-53-5 HCAPLUS
CN Acetamide, N-[[2-oxo-3-[2-[(2-pyridinylmethyl)amino]-6-benzoxazolyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 176491-54-6 HCAPLUS
CN Acetamide, N-[[3-[2-[[3-(dimethylamino)propyl]methylamino]-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-55-7 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[6-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-benzoxazolyl]-, 1,1-dimethylethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-56-8 HCAPLUS
CN Acetamide, N-[[2-oxo-3-[2-(1-piperazinyl)-6-benzoxazolyl]-5-oxazolidinyl]methyl]-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

Updated Search

RN 176491-57-9 HCAPLUS
CN Acetamide, N-[[2-oxo-3-[2-(4-oxo-1-piperidinyl)-6-benzoxazolyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176491-58-0 HCAPLUS
CN Acetamide, N-[[2-oxo-3-[2-[(2-pyridinylmethyl)amino]-6-benzoxazolyl]-5-oxazolidinyl]methyl]-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 176491-59-1 HCAPLUS
CN Propanamide, 2-[[6-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-benzoxazolyl]amino]-N-methyl- (9CI) (CA INDEX NAME)



L23 ANSWER 40 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:241534 HCAPLUS
DOCUMENT NUMBER: 124:289520
TITLE: Preparation of 3-heteroaryl-2-oxazolidinones as antibacterials.
INVENTOR(S): Riedl, Bernd; Haebich, Dieter; Stolle, Andreas; Wild, Hanno; Endermann, Rainer; Bremm, Klaus Dieter; Kroll, Hein-Peter; Labischinski, Harald; Schaller, Klaus; Werling, Hans-Otto
PATENT ASSIGNEE(S): Bayer A.-G., Germany

Updated Search

SOURCE: Eur. Pat. Appl., 62 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 693491	A1	19960124	EP 1995-110629	19950707
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
DE 4425613	A1	19960125	DE 1994-4425613	19940720
RO 115161	B1	19991130	RO 1995-1295	19950711
AU 9524988	A1	19960201	AU 1995-24988	19950713
AU 695661	B2	19980820		
CA 2154026	AA	19960121	CA 1995-2154026	19950717
US 5698574	A	19971216	US 1995-503183	19950717
IL 114622	A1	19990714	IL 1995-114622	19950717
FI 9503476	A	19960121	FI 1995-3476	19950718
JP 08053443	A2	19960227	JP 1995-203904	19950718
NO 9502866	A	19960122	NO 1995-2866	19950719
ZA 9506015	A	19960222	ZA 1995-6015	19950719
CN 1121919	A	19960508	CN 1995-108995	19950719
HU 74003	A2	19961028	HU 1995-2167	19950719

PRIORITY APPLN. INFO.: DE 1994-4425613 A 19940720
OTHER SOURCE(S): MARPAT 124:289520
GI



I II

AB Title compds. [I; R1 = N3, OH, OR2, OSO3R3, NR4R5; R2 = acyl, protecting group; R3 = alkyl, (alkyl-substituted) Ph; R, R5 = H, alkyl, cycloalkyl, Ph, acyl; A = C-bonded (substituted) 5-membered heteroaryl which may be benzo- or naphtho-fused], were prepared Thus, 4-bromobenzo[b]thiophene-2-carboxylic acid and Et3N in acetone at 0° were treated with iso-Bu chloroformate and then with NaN3 to give 76% 4-bromobenzo[b]thiophene-2-carbonyl azide. The latter was refluxed 1 h with LiBr and Bu3PO in xylene using a water separator; (R)-glycidyl butyrate in xylene was added at reflux to give 30% (5R)-3-[4-bromobenzo[b]thiophenyl]-5-butyryloxymethyloxazolidin-2-one. This was stirred with cesium carbonate in MeOH to give 61% title compound (II). I inhibited Staph. 133 with a min. inhibitory concentration of 0.25-16 μg/mL.

IT 175591-46-5P 175591-47-6P 175591-48-7P
175591-49-8P 175591-57-8P 175591-58-9P
175591-61-4P 175591-90-9P 175591-91-0P
175591-92-1P 175591-93-2P 175591-94-3P
175591-95-4P 175591-96-5P 175591-97-6P
175591-98-7P 175592-05-9P 175592-06-0P
175592-09-3P 175592-10-6P 175592-11-7P
175592-12-8P 175592-13-9P 175592-14-0P
175592-15-1P 175592-16-2P 175592-17-3P

Updated Search

175592-18-4P 175592-19-5P 175592-20-8P
175592-21-9P 175592-22-0P 175592-23-1P
175592-24-2P 175592-37-7P 175592-38-8P
175592-39-9P 175592-40-2P 175592-41-3P
175592-43-5P 175592-45-7P 175592-46-8P
175592-47-9P 175592-49-1P 175592-50-4P
175592-51-5P 175592-52-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-heteroaryl-2-oxazolidinones as antibacterials)

RN 175591-46-5 HCAPLUS
CN Acetamide, N-[[3-(4-bromobenzo[b]thien-2-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175591-47-6 HCAPLUS
CN Acetamide, N-[[3-(5-bromobenzo[b]thien-2-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 175591-48-7 HCAPLUS
CN Acetamide, N-[[3-(6-bromobenzo[b]thien-2-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175591-49-8 HCAPLUS

Updated Search

CN Acetamide, N-[[3-(7-bromobenzo[b]thien-2-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 175591-57-8 HCAPLUS
CN Acetamide, N-[[3-(6-bromo-2-benzothiazolyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175591-58-9 HCAPLUS
CN Acetamide, N-[[3-(5-bromo-2-benzofuranyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175591-61-4 HCAPLUS
CN Acetamide, N-[[3-(2-benzofuranyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175591-90-9 HCAPLUS

Updated Search

CN Acetamide, N-[[2-oxo-3-(4-phenylbenzo[b]thien-2-yl)-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175591-91-0 HCAPLUS
CN Acetamide, N-[[3-[4-(4-methylphenyl)benzo[b]thien-2-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 175591-92-1 HCAPLUS
CN Acetamide, N-[[3-[4-(2-formylphenyl)benzo[b]thien-2-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



Updated Search

RN 175591-93-2 HCAPLUS
CN Acetamide, N-[[3-[4-(3-formylphenyl)benzo[b]thien-2-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 175591-94-3 HCAPLUS
CN Acetamide, N-[[3-[4-(4-formylphenyl)benzo[b]thien-2-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 175591-95-4 HCAPLUS
CN Acetamide, N-[[3-[4-(4-acetylphenyl)benzo[b]thien-2-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Updated Search



RN 175591-96-5 HCAPLUS
CN Acetamide, N-[[3-[4-(4-fluorophenyl)benzo[b]thien-2-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 175591-97-6 HCAPLUS
CN Acetamide, N-[[3-[4-(3-aminophenyl)benzo[b]thien-2-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Updated Search



RN 175591-98-7 HCAPLUS
CN Acetamide, N-[[3-[4-(3-acetylphenyl)benzo[b]thien-2-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 175592-05-9 HCAPLUS
CN Acetamide, N-[[3-[5-(3-acetylphenyl)benzo[b]thien-2-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175592-06-0 HCAPLUS
CN Acetamide, N-[[3-[5-(4-fluorophenyl)benzo[b]thien-2-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Updated Search



RN 175592-09-3 HCAPLUS
CN Acetamide, N-[[3-[5-(4-acetylphenyl)benzo[b]thien-2-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175592-10-6 HCAPLUS
CN Acetamide, N-[[3-[5-(3-aminophenyl)benzo[b]thien-2-yl]-2-oxo-5-oxazolidinyl]methyl]-, hydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● x HCl

RN 175592-11-7 HCAPLUS
CN Acetamide, N-[[3-[5-(3-chloro-4-fluorophenyl)benzo[b]thien-2-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Updated Search



RN 175592-12-8 HCAPLUS
CN Acetamide, N-[[3-[5-[3,5-bis(trifluoromethyl)phenyl]benzo[b]thien-2-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 175592-13-9 HCAPLUS
CN Acetamide, N-[[3-[4-(5-formyl-3-thienyl)benzo[b]thien-2-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 175592-14-0 HCAPLUS
CN Acetamide, N-[[3-[4-(3-chloro-4-fluorophenyl)benzo[b]thien-2-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Updated Search



RN 175592-15-1 HCAPLUS
CN Acetamide, N-[[3-[4-[3,5-bis(trifluoromethyl)phenyl]benzo[b]thien-2-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 175592-16-2 HCAPLUS
CN Acetamide, N-[[3-[4-(4-methoxyphenyl)benzo[b]thien-2-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 175592-17-3 HCAPLUS
CN Acetamide, N-[[2-oxo-3-(7-phenylbenzo[b]thien-2-yl)-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Updated Search

Absolute stereochemistry.



RN 175592-18-4 HCAPLUS
CN Acetamide, N-[[3-[7-(3-formylphenyl)benzo[b]thien-2-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175592-19-5 HCAPLUS
CN Acetamide, N-[[3-[5-(4-formylphenyl)benzo[b]thien-2-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 175592-20-8 HCAPLUS
CN Acetamide, N-[[2-oxo-3-(5-phenylbenzo[b]thien-2-yl)-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 175592-21-9 HCAPLUS
CN Acetamide, N-[[3-[5-(3-formylphenyl)benzo[b]thien-2-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 175592-22-0 HCAPLUS
CN Acetamide, N-[[3-[5-(5-acetyl-2-thienyl)benzo[b]thien-2-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 175592-23-1 HCAPLUS
CN Acetamide, N-[[3-[7-(4-formylphenyl)benzo[b]thien-2-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 175592-24-2 HCAPLUS
CN Acetamide, N-[[3-[7-(4-fluorophenyl)benzo[b]thien-2-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175592-37-7 HCAPLUS
CN Acetamide, N-[[3-(5-fluorobenzo[b]thien-2-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 175592-38-8 HCAPLUS
CN Acetamide, N-[[3-(5-methylbenzo[b]thien-2-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Updated Search

Absolute stereochemistry. Rotation (-).



RN 175592-39-9 HCAPLUS
CN Acetamide, N-[[3-(5-cyanobenzo[b]thien-2-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175592-40-2 HCAPLUS
CN Acetamide, N-[[3-(6-fluorobenzo[b]thien-2-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175592-41-3 HCAPLUS
CN Acetamide, N-[[3-(6-chlorobenzo[b]thien-2-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175592-43-5 HCAPLUS
CN Benzoic acid, 4-[2-[5-[(acetylamino)methyl]-2-oxo-3-

Updated Search

oxazolidinyl]benzo[b]thien-5-yl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175592-45-7 HCAPLUS
CN Acetamide, N-[[3-[6-(4-formylphenyl)benzo[b]thien-2-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175592-46-8 HCAPLUS
CN Acetamide, N-[[3-[6-(4-acetylphenyl)benzo[b]thien-2-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175592-47-9 HCAPLUS
CN Acetamide, N-[[3-(6-[1,1'-biphenyl]-4-ylbenzo[b]thien-2-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 175592-49-1 HCAPLUS
CN Benzo[b]thiophene-4-carboxylic acid, 2-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175592-50-4 HCAPLUS
CN Benzo[b]thiophene-6-carboxylic acid, 2-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175592-51-5 HCAPLUS
CN Benzo[b]thiophene-5-carboxylic acid, 2-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 175592-52-6 HCAPLUS
CN Acetamide, N-[(3-benzo[b]thien-2-yl-2-oxo-5-oxazolidinyl)methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L23 ANSWER 41 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:231381 HCAPLUS
DOCUMENT NUMBER: 124:261020
TITLE: Preparation of benzofuranyl- and benzothienyloxazolidinones as antibacterials.
INVENTOR(S): Riedl, Bernd; Haebich, Dieter; Stolle, Andreas; Wild, HannoEndermann, Rainer; Endermann, Rainer; Bremm, Klaus-Dieter; Kroll, Hein-Peter; Labischinski, Harald; Schaller, Klaus; Werling, Hans-Otto
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Ger. Offen., 34 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4425609	A1	19960125	DE 1994-4425609	19940720
EP 694544	A1	19960131	EP 1995-110628	19950707
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2154024	AA	19960121	CA 1995-2154024	19950717
US 5684023	A	19971104	US 1995-503116	19950717
JP 08041057	A2	19960213	JP 1995-205247	19950719

PRIORITY APPLN. INFO.: DE 1994-4425609 A 19940720
OTHER SOURCE(S): MARPAT 124:261020
GI

Updated Search



I



II

AB Title compds. [I; R1 = N3, OH, OR2, OSO2R3, NR4R5; R2 = acyl, protecting group; R3 = alkyl, (substituted) Ph; r4, R5 = H, cycloalkyl, Ph, protecting group, COR6; R6 = H, cycloalkyl, alkyl, alkoxy, Ph; A = O, S; D, E, G, L, M = H, CO2H, halo, cyano, mercapto, formyl, CF3, NO2, alkyl, alkoxy, alkoxycarbonyl, alkylthio, acyl, etc.], and their salts and S-oxides, were prepared Thus, 5-benzyloxycarbonylaminobenzo[b]thiophene (preparation given) and 1,10-phenanthroline in THF at -70° were treated with BuLi and then with (R)-glycidyl butyrate to give title compound (II). Selected I showed min. inhibitory concns. of 1-16 μg/mL against Staph. 133.

IT 175424-85-8P 175424-86-9P 175424-87-0P
175424-88-1P 175424-89-2P 175424-92-7P
175424-93-8P 175424-94-9P 175424-95-0P
175424-96-1P 175424-97-2P 175424-98-3P
175424-99-4P 175425-00-0P 175425-01-1P
175425-02-2P 175425-03-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzofuranyl- and benzothienyloxazolidinones as antibacterials)

RN 175424-85-8 HCAPLUS

CN Acetamide, N-[(3-benzo[b]thien-5-yl-2-oxo-5-oxazolidinyl)methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175424-86-9 HCAPLUS

CN Acetamide, N-[[3-(3-methylbenzo[b]thien-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

RN 175424-87-0 HCAPLUS
CN Benzo[b]thiophene-2-carboxylic acid, 5-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175424-88-1 HCAPLUS
CN Acetamide, N-[[2-oxo-3-(2-phenylbenzo[b]thien-5-yl)-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175424-89-2 HCAPLUS
CN Propanamide, N-[[2-oxo-3-(2-phenylbenzo[b]thien-5-yl)-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175424-92-7 HCAPLUS
CN Acetamide, N-[[3-(2-methylbenzo[b]thien-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

RN 175424-93-8 HCAPLUS
CN Acetamide, N-[[3-(2-bromobenzo[b]thien-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175424-94-9 HCAPLUS
CN Acetamide, N-[[3-(2-bromo-3-methylbenzo[b]thien-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175424-95-0 HCAPLUS
CN Acetamide, N-[[3-(3-bromo-2-methylbenzo[b]thien-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175424-96-1 HCAPLUS
CN Acetamide, N-[[3-(3-bromo-2-phenylbenzo[b]thien-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175424-97-2 HCAPLUS

Updated Search

CN Acetamide, N-[[3-[2-(4-formylphenyl)-3-methylbenzo[b]thien-5-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175424-98-3 HCAPLUS
CN Acetamide, N-[[3-[2-(4-formylphenyl)benzo[b]thien-5-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175424-99-4 HCAPLUS
CN Acetamide, N-[[3-[2-(4-acetylphenyl)benzo[b]thien-5-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175425-00-0 HCAPLUS
CN Acetamide, N-[[3-[2-(4-fluorophenyl)benzo[b]thien-5-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

RN 175425-01-1 HCAPLUS
CN Acetamide, N-[[2-oxo-3-[2-(3-pyridinyl)benzo[b]thien-5-yl]-5-oxazolidinyl]methyl]-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 175425-02-2 HCAPLUS
CN Acetamide, N-[[3-(2-bromo-3-methyl-1,1-dioxidobenzo[b]thien-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175425-03-3 HCAPLUS
CN Acetamide, N-[[3-(1,1-dioxidobenzo[b]thien-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L23 ANSWER 42 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:228503 HCAPLUS
DOCUMENT NUMBER: 124:261021
TITLE: Six-membered nitrogen-containing heteroaryl oxazolidinones useful as antibacterials
INVENTOR(S): Riedl, Bernd; Haebich, Dieter; Stolle, Andreas; Wild,

Updated Search

Hanno; Endermann, Rainer; Bremm, Klaus Dieter; Kroll, Hein-Peter; Labischinski, Harald; Schaller, Klaus; Werling, Hans-Otto

PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Eur. Pat. Appl., 99 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 694543	A1	19960131	EP 1995-110624	19950707
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
DE 4425612	A1	19960404	DE 1994-4425612	19940720
AU 9524985	A1	19960201	AU 1995-24985	19950713
AU 699940	B2	19981217		
RO 115262	B1	19991230	RO 1995-1312	19950714
CA 2154025	AA	19960121	CA 1995-2154025	19950717
JP 08041056	A2	19960213	JP 1995-201799	19950717
US 5627181	A	19970506	US 1995-503369	19950717
IL 114626	A1	19990817	IL 1995-114626	19950717
FI 9503477	A	19960121	FI 1995-3477	19950718
NO 9502865	A	19960122	NO 1995-2865	19950719
ZA 9506018	A	19960313	ZA 1995-6018	19950719
HU 75035	A2	19970328	HU 1995-2173	19950719
CN 1119647	A	19960403	CN 1995-107584	19950720
US 5843967	A	19981201	US 1996-749581	19961115

PRIORITY APPLN. INFO.: DE 1994-4425612 A 19940720
US 1995-503369 A1 19950717

OTHER SOURCE(S): MARPAT 124:261021
GI



I



II



III

AB The title compds. I are prepared [in which R1 = N3, OH, OR2, OSO2R3, NR4R5;

Updated Search

R2 = acyl, protecting group; R3 = alkyl, Ph, alkylphenyl; R4, R5 = cycloalkyl, H, Ph, alkyl, protecting group, COR6; R6 = cycloalkyl, alkyl, Ph, H; D = [all optionally substituted] C-bound, 6-membered, aromatic, N-containing heterocyclyl; or 6-membered-ring-containing bi- or tricyclic aromatic N-containing heterocyclyl; or β-carbolin-3-yl; or indolizinyl]. For example, cyclization of 5-bromo-2-isocyanatopyridine-HCl with (R)-glycidyl butyrate in the presence of Bu3P:O in xylene gave 26% title compound II. This was subjected to a sequence of ester methanolysis (69%), conversion of the resulting alc. to a mesylate (95%), then to an azide (95%), and then to an amine (85%), N-acetylation of the amine (98%), and Pd0-catalyzed coupling with 4-MeC6H4B(OH)2 (60%), to give title compound III [R = Me]. The analogously prepared compound III [R = H] had MIC of 0.5-1 μg/mL against 4 strains of Staphylococcus.

IT 175391-91-0P 175391-92-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heteroaryloxazolidinones as antibacterials)

RN 175391-91-0 HCAPLUS
CN Acetamide, N-[[2-oxo-3-(2-quinolinyl)-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175391-92-1 HCAPLUS
CN Acetamide, N-[[2-oxo-3-(6-quinolinyl)-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 175391-93-2P 175391-95-4P 175391-96-5P
175391-97-6P 175391-98-7P 175392-15-1P
175392-16-2P 175392-17-3P 175392-18-4P
175392-19-5P 175392-20-8P 175392-21-9P
175392-22-0P 175392-24-2P 175392-25-3P
175392-26-4P 175392-27-5P 175392-63-9P
175392-64-0P 175392-65-1P 175392-66-2P
175392-67-3P 175392-90-2P 175392-91-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

Updated Search

BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroaryloxazolidinones as antibacterials)

RN 175391-93-2 HCAPLUS
CN Acetamide, N-[[2-oxo-3-(2-quinoxalinyl)-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175391-95-4 HCAPLUS
CN Acetamide, N-[[3-(3-methyl-6-quinolinyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175391-96-5 HCAPLUS
CN Acetamide, N-[[3-(3-bromo-6-quinolinyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175391-97-6 HCAPLUS
CN Acetamide, N-[[3-(6-bromo-2-quinolinyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 175391-98-7 HCAPLUS
CN Acetamide, N-[[3-(8-bromo-2-quinolinyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175392-15-1 HCAPLUS
CN Acetamide, N-[[3-[6-(5-methoxy-2-thienyl)-2-quinolinyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175392-16-2 HCAPLUS
CN Acetamide, N-[[3-[6-(3-formylphenyl)-2-quinolinyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175392-17-3 HCAPLUS

Updated Search

CN Acetamide, N-[[3-[6-(4-methylphenyl)-2-quinolinyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175392-18-4 HCAPLUS
CN Acetamide, N-[[3-[8-(3-formylphenyl)-2-quinolinyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175392-19-5 HCAPLUS
CN Acetamide, N-[[3-[8-[3,5-bis(trifluoromethyl)phenyl]-2-quinolinyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175392-20-8 HCAPLUS
CN Acetamide, N-[[3-[8-(5-acetyl-2-thienyl)-2-quinolinyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 175392-21-9 HCAPLUS
CN Acetamide, N-[[3-[8-(4-methylphenyl)-2-quinolinyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175392-22-0 HCAPLUS
CN Acetamide, N-[[3-[6-(4-acetylphenyl)-2-quinolinyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175392-24-2 HCAPLUS
CN Acetamide, N-[[2-oxo-3-(6-quinolinyl)-5-oxazolidinyl]methyl]-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



● HCl

RN 175392-25-3 HCAPLUS
CN Quinolinium, 6-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1-methyl-, iodide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● I⁻

RN 175392-26-4 HCAPLUS
CN Quinolinium, 6-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1-ethyl-, iodide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● I⁻

RN 175392-27-5 HCAPLUS
CN Acetamide, N-[[3-(1-oxido-6-quinolinyl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Updated Search

Absolute stereochemistry.



RN 175392-63-9 HCAPLUS
CN Acetamide, N-[[3-[3-(4-fluorophenyl)-6-quinolinyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175392-64-0 HCAPLUS
CN Acetamide, N-[[3-[3-(4-formylphenyl)-6-quinolinyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175392-65-1 HCAPLUS
CN Acetamide, N-[[3-[3-(4-acetylphenyl)-6-quinolinyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

RN 175392-66-2 HCAPLUS
CN Acetamide, N-[[2-oxo-3-(3-phenyl-6-quinolinyl)-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175392-67-3 HCAPLUS
CN Acetamide, N-[[2-oxo-3-[3-(3-pyridinyl)-6-quinolinyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175392-90-2 HCAPLUS
CN Acetamide, N-[[3-(3-bromo-6-quinolinyl)-2-oxo-5-oxazolidinyl]methyl]-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 175392-91-3 HCAPLUS
CN Acetamide, N-[[2-oxo-3-(2-quinoxalinyl)-5-oxazolidinyl]methyl]-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



● HCl

L23 ANSWER 43 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:858608 HCAPLUS
DOCUMENT NUMBER: 123:256757
TITLE: Preparation of indolo[2,1-b]quinazoline-6,12-dione tuberculostatics
INVENTOR(S): Baker, William R.; Mitscher, Lester A.
PATENT ASSIGNEE(S): Pathogenesis Corp., USA
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9513807	A1	19950526	WO 1994-US13259	19941117
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5441955	A	19950815	US 1993-154784	19931119
AU 9512100	A1	19950606	AU 1995-12100	19941117
PRIORITY APPLN. INFO.:			US 1993-154784 A	19931119
			WO 1994-US13259 W	19941117

OTHER SOURCE(S): MARPAT 123:256757
GI

Updated Search



I



II

AB The title compds. [I; A-H = C, N; or A and B or C and D can be taken together to be N or S; R1-R4, R8, R10 = H, halogen, alkyl, cycloalkyl, (un)substituted heterocyclyl, (un)substituted amino, NO2, CN, CHO, etc.; R7, R9 = H, halogen, (un)substituted alkyl, cycloalkyl, (un)substituted heterocyclyl] useful for the treatment of multidrug-resistant Mycobacterium tuberculosis and M. leprae, are prepared Thus, 5-fluoroisatin was added to a solution of Me3COK and N-methylpyrrolidone, producing 8-fluoroindolo[2,1-b]quinazoline-6,12-dione, II, m.p. 273-276°, which demonstrated a MIC against multiple drug-resistant M. tuberculosis (10038) of <1 μg/mL, vs. 10 μg/mL for tryptanthrin.

IT 169038-12-4P 169038-13-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indolo[2,1-b]quinazoline-6,12-dione tuberculostatics)

RN 169038-12-4 HCAPLUS

CN Acetamide, N-[[3-(8-fluoro-6,12-dihydro-6,12-dioxoindolo[2,1-b]quinazolin-3-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 169038-13-5 HCAPLUS

CN Acetamide, N-[[3-(8-fluoro-6,12-dihydro-6,12-dioxoindolo[2,1-b]quinazolin-2-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Updated Search



L23 ANSWER 44 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1993:649939 HCAPLUS
DOCUMENT NUMBER: 119:249939
TITLE: Antidepressants containing naphthyloxazolidones
INVENTOR(S): Nakai, Hideo; Yamada, Koichiro; Nomura, Sumihiro; Matsumoto, Mamoru; Iwata, Hiroshi
PATENT ASSIGNEE(S): Tanabe Seiyaku Co, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05155772	A2	19930622	JP 1992-151103	19920423
JP 2551298	B2	19961106		
PRIORITY APPLN. INFO.:			JP 1991-191353 A1	19910425

OTHER SOURCE(S): MARPAT 119:249939
GI



I

AB Antidepressants contain naphthyloxazolidones I [R1 = H, OH, NO2, NH2, SO3H, aminosulfonyl, lower alkenyloxy, lower alkynyloxy, mono- or di-lower alkylaminocarbonyloxy, lower alkanoyloxy, lower alkoxy (which may be substituted with aryl, cycloalkyl, O-containing monoheterocyclyl, OH, lower alkoxy, cyano, di-lower alkylamino, aminocarbonyl, lower alkoxycarbonyl, lower alkanoyloxy, lower alkylthio, lower alkylsufinyl, lower alkylsulfonyl); R2 = OH, lower alkoxy, lower alkylsufonyloxy, N3, (lower alkyl- or alkanoyl-substituted) NH2] or their pharmacol. acceptable salts as active ingredients. Condensation of 20.0 g 2-naphthylamine with 16.7 g ethoxycarbonyl chloride in CH2Cl2 at room temperature overnight gave 25.26 g N-ethoxycarbonyl-2-naphthylamine, which (3.82 g) was refluxed with 3.13 g 2-(methoxymethyl)oxirane and Et3N for 3.5 h to afford 3.17 g 3-(2-naphthyl)-5-methoxymethyl-2-oxazolidone. The product at 10-7 M inhibited 78.4% MAO-A.

IT 135205-29-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

Updated Search

(preparation of, as antidepressant)
RN 135205-29-7 HCAPLUS
CN Acetamide, N-[[3-(2-naphthalenyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



L23 ANSWER 45 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1992:151623 HCAPLUS
DOCUMENT NUMBER: 116:151623
TITLE: Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 4. Multiply-substituted aryl derivatives
AUTHOR(S): Park, Chung Ho; Brittelli, David R.; Wang, C. L. J.; Marsh, Frank D.; Gregory, Walter A.; Wuonola, Mark A.; McRipley, Ronald J.; Eberly, Virginia S.; Slee, Andrew M.; Forbes, Martin
CORPORATE SOURCE: Drug Discovery Res., Chem. Sci., Exp. Stn., Du Pont Merck Pharm. Co., Wilmington, DE, 19880-0353, USA
SOURCE: Journal of Medicinal Chemistry (1992), 35(6), 1156-65
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The synthesis and structure-activity relationship (SAR) studies of the effect of different polysubstitution patterns in the aromatic ring of 5-(acetamidomethyl)oxazolidinones, e.g., (I Ar = substituted Ph, 5-indolyl, β-naphthyl) on antibacterial activity are presented. Compds. I were prepared by the six-step synthesis described previously via electrophilic aromatic substitution reactions of 3-substituted compds., and functional-group interchange reactions of 3,4-disubstituted compds. Antibacterial evaluation of compds. I against Staphylococcus aureus and Enterococcus faecalis gave the following results. The 2,4- and 2,5-disubstituted derivs. have weak or no antibacterial activity. Antibacterial activities of 3,4-disubstituted compds. are comparable to those of the 4-monosubstituted analogs for small 3-substituents (smaller than Br), but decline rapidly for larger 3-substituents. 3,4-Annulated derivs. are comparable in activity to their open-chain analogs. 3,5-Disubstituted and 3,4,5- and 2,4,6-trisubstituted derivs. are devoid of antibacterial activity.

Updated Search

IT 120912-42-7P 120912-43-8P 139071-73-1P
139071-74-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antibacterial activity of)

RN 120912-42-7 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-1H-inden-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 120912-43-8 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-1-oxo-1H-inden-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 139071-73-1 HCAPLUS
CN Acetamide, N-[[3-(1H-indol-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 139071-74-2 HCAPLUS
CN Acetamide, N-[[(5S)-3-(2-naphthalenyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



L23 ANSWER 46 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1991:471581 HCAPLUS
DOCUMENT NUMBER: 115:71581
TITLE: Preparation of naphthyloxazolidone derivatives as selective monoamine oxidase A inhibitors
INVENTOR(S): Nakai, Hideo; Yamada, Koichiro; Nomura, Sumihiro; Matsumoto, Mamoru; Iwata, Hiroshi
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 30 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 425209	A2	19910502	EP 1990-311524	19901019
EP 425209	A3	19920219		
EP 425209	B1	19950510		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5182296	A	19930126	US 1990-599564	19901018
AT 122344	E	19950515	AT 1990-311524	19901019
ES 2074544	T3	19950916	ES 1990-311524	19901019
CA 2028440	AA	19910427	CA 1990-2028440	19901024
CA 2028440	C	19961112		
JP 03218367	A2	19910925	JP 1990-289910	19901025
KR 128288	B1	19980402	KR 1990-17252	19901026
US 5332754	A	19940726	US 1992-961873	19921015
PRIORITY APPLN. INFO.:			JP 1989-279305 A	19891026
			US 1990-599564 A1	19901018

OTHER SOURCE(S): MARPAT 115:71581
GI



I

AB Title compds. [I; R1 = H, OH, NO2, amino, sulfo, aminosulfonyl, alkenyloxy, alkynyloxy, alkylaminocarbonyloxy, alkanoyloxy, (substituted) alkoxy; R2 = OH, alkoxy, alkylsulfonyloxy, triazo, amino], were prepared Thus, EtO2CCl, 2-naphthylamine, NaHCO3, and CH2Cl2 were stirred overnight to give N-ethoxycarbonyl-2-naphthylamine. The latter was refluxed with 2-methoxymethyloxirane and Et3N to give 5-methoxymethyl-3-(2-naphthyl)-2-

Updated Search

oxazolidene. I at 10-7 M gave 76.6-98.8% inhibition of MAO-A (monoamine oxidase A) from rat cerebral mitochondria; they were selective for MAO-A over MAO-B.

IT 135205-29-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as monoamine oxidase A inhibitor)

RN 135205-29-7 HCAPLUS

CN Acetamide, N-[[3-(2-naphthalenyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



L23 ANSWER 47 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1990:572004 HCAPLUS
DOCUMENT NUMBER: 113:172004
TITLE: Preparation of 5β-amidomethyloxazolidin-2-ones as antibacterial agents
INVENTOR(S): Brickner, Steven L.
PATENT ASSIGNEE(S): Upjohn Co., USA
SOURCE: Eur. Pat. Appl., 75 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 359418	A1	19900321	EP 1989-308506	19890822
EP 359418	B1	19941012		
R: ES, GR				
WO 9002744	A1	19900322	WO 1989-US3548	19890822
W: AU, DK, FI, HU, JP, KR, NO, SU, US				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
AU 8941957	A1	19900402	AU 1989-41957	19890822
AU 617871	B2	19911205		
EP 434714	A1	19910703	EP 1989-909990	19890822
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 04500665	T2	19920206	JP 1989-509255	19890822
JP 2865211	B2	19990308		
EP 609905	A1	19940810	EP 1994-102762	19890822
EP 609905	B1	20010606		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
ES 2157934	T3	20010901	ES 1994-102762	19890822
CA 1335103	A1	19950404	CA 1989-609594	19890828
KR 138262	B1	19980515	KR 1990-701012	19900514
US 5164510	A	19921117	US 1991-655419	19910220
DK 9100455	A	19910313	DK 1991-455	19910313
DK 175696	B1	20050124		
US 5182403	A	19930126	US 1992-872557	19920423
US 5225565	A	19930706	US 1992-872871	19920423
JP 11080139	A2	19990326	JP 1998-191949	19980707

Updated Search

JP 3188418	B2	20010716			
GR 3036491	T3	20011130	GR 2001-401350		20010831
LV 12888	B	20021220	LV 2002-104		20020606
DK 2004001246	A5	20040818	DK 2004-1246		20040818
DK 175940	B1	20050801			

PRIORITY APPLN. INFO.:

US 1988-244988	A	19880915
US 1988-253850	A	19881005
US 1989-324942	A	19890317
EP 1989-308506	A3	19890822
JP 1989-509255	A3	19890822
WO 1989-US3548	A	19890822
US 1991-655419	A3	19910220
DK 1991-455	L	19910313

OTHER SOURCE(S): MARPAT 113:172004

GI For diagram(s), see printed CA Issue.

AB The title compds. [I; W1, W2 = H, alkyl, etc., or W1W2 = NR5CH:CR7, NR5CH2CH2; R2-R5, R7 = H, alkyl, acyl, etc.; R6 = amido, e.g. NHAc], useful as antibacterials against gram-pos. and anaerobic infections, and against Mycobacterium avium in AIDS patients (no data), were prepared 3-(1-Acetyl-1H-indolin-5-yl)-5-(azidomethyl)-2-oxazolidinone (preparation given) was hydrogenated over Pd/C and the resulting amine acetylated with Ac2O to give 3-(1-acetyl-1H-indolin-5-yl)-5-(acetamidomethyl)-2-oxazolidinone.

IT 129487-98-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of antibacterials)

RN 129487-98-5 HCAPLUS

CN 1H-Indole-1-carboxylic acid, 5-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,3-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 120912-44-9P 129487-31-6P 129487-32-7P
129487-33-8P 129487-34-9P 129487-35-0P
129487-36-1P 129487-37-2P 129487-38-3P
129487-39-4P 129487-40-7P 129487-41-8P
129487-42-9P 129487-43-0P 129487-44-1P
129487-45-2P 129487-46-3P 129487-47-4P
129487-48-5P 129487-49-6P 129487-52-1P
129487-53-2P 129487-54-3P 129487-55-4P
129487-56-5P 129487-57-6P 129487-58-7P
129487-59-8P 129487-60-1P 129487-61-2P
129487-62-3P 129487-63-4P 129487-64-5P
129487-65-6P 129487-66-7P 129487-67-8P
129487-73-6P 129487-74-7P 129487-75-8P
129487-76-9P 129487-77-0P 129487-78-1P
129487-79-2P 129487-80-5P 129487-81-6P
129487-82-7P 129487-83-8P 129487-84-9P
129487-85-0P 129487-86-1P 129491-47-0P
129502-53-0P 129567-77-7P 129567-78-8P

Updated Search

129567-79-9P 129567-80-2P 129567-81-3P
129567-82-4P 129567-83-5P 129567-84-6P
129567-85-7P 129567-86-8P 129567-87-9P
129567-88-0P 129567-89-1P 129567-90-4P
129567-91-5P 129567-95-9P 129567-96-0P
129567-98-2P 129567-99-3P 129568-00-9P
129568-01-0P 129568-02-1P 129568-71-4P
129568-72-5P 129645-53-0P 129954-20-7P
129954-21-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antibacterial)

RN 120912-44-9 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-1-hydroxy-1H-inden-5-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 129487-31-6 HCAPLUS
CN Acetamide, N-[[3-(1-acetyl-2,3-dihydro-1H-indol-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129487-32-7 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-1H-indol-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

RN 129487-33-8 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-1-(2-methylpropyl)-1H-indol-5-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129487-34-9 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-1-(1-oxopropyl)-1H-indol-5-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129487-35-0 HCAPLUS
CN Acetamide, N-[[3-[1-(cyclopentylcarbonyl)-2,3-dihydro-1H-indol-5-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129487-36-1 HCAPLUS
CN Acetamide, N-[[3-(1-formyl-2,3-dihydro-1H-indol-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Updated Search

Absolute stereochemistry.



RN 129487-37-2 HCAPLUS
CN Acetamide, N-[[3-[1-(dichloroacetyl)-2,3-dihydro-1H-indol-5-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129487-38-3 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-1-(phenylacetyl)-1H-indol-5-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129487-39-4 HCAPLUS
CN Acetamide, N-[[3-[1-[(acetyloxy)acetyl]-2,3-dihydro-1H-indol-5-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 129487-40-7 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-1-(2-thienylcarbonyl)-1H-indol-5-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129487-41-8 HCAPLUS
CN Acetamide, N-[[3-(1-benzoyl-2,3-dihydro-1H-indol-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129487-42-9 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-1-methyl-1H-indol-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 129487-43-0 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-1-(hydroxyacetyl)-1H-indol-5-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129487-44-1 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-1-[(phenylmethoxy)acetyl]-1H-indol-5-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129487-45-2 HCAPLUS
CN Acetamide, N-[[3-[1-(4-chlorobenzoyl)-2,3-dihydro-1H-indol-5-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 129487-46-3 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-1-(2-propenyl)-1H-indol-5-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129487-47-4 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-1-propyl-1H-indol-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129487-48-5 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-1-(methoxyacetyl)-1H-indol-5-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 129487-49-6 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-1-(1-oxohexyl)-1H-indol-5-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129487-52-1 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-2-methyl-1-oxo-1H-inden-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129487-53-2 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-2-methyl-1-oxo-1H-inden-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 129487-54-3 HCAPLUS
CN Acetamide, N-[[3-(2-ethyl-2,3-dihydro-1-oxo-1H-inden-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129487-55-4 HCAPLUS
CN Acetamide, N-[[3-(1',3'-dihydro-1'-oxospiro[cyclopropane-1,2'-[2H]inden]-5'-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129487-56-5 HCAPLUS
CN Acetamide, N-[[2-oxo-3-(5,6,7,8-tetrahydro-6-methyl-5-oxo-2-naphthalenyl)-5-oxazolidinyl]methyl]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129487-57-6 HCAPLUS

Updated Search

CN Acetamide, N-[[2-oxo-3-(5,6,7,8-tetrahydro-6-methyl-5-oxo-2-naphthalenyl)-5-oxazolidinyl]methyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129487-58-7 HCAPLUS
CN Acetamide, N-[[3-(3',4'-dihydro-1'-oxospiro[cyclopropane-1,2'(1'H)-naphthalen]-6'-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129487-59-8 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-2-(hydroxymethyl)-1-oxo-1H-inden-5-yl]-2-oxo-5-oxazolidinyl]methyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129487-60-1 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-2-(hydroxymethyl)-1-oxo-1H-inden-5-yl]-2-oxo-5-oxazolidinyl]methyl]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 129487-61-2 HCAPLUS
CN Acetamide, N-[[2-oxo-3-[5,6,7,8-tetrahydro-6-(hydroxymethyl)-5-oxo-2-naphthalenyl]-5-oxazolidinyl]methyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129487-62-3 HCAPLUS
CN Acetamide, N-[[2-oxo-3-[5,6,7,8-tetrahydro-6-(hydroxymethyl)-5-oxo-2-naphthalenyl]-5-oxazolidinyl]methyl]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129487-63-4 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-2,2-dimethyl-1-oxo-1H-inden-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

RN 129487-64-5 HCAPLUS
CN Acetamide, N-[[2-oxo-3-(5,6,7,8-tetrahydro-6,6-dimethyl-5-oxo-2-naphthalenyl)-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129487-65-6 HCAPLUS
CN 1H-Indole-1-carboxylic acid, 6-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,3-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 129487-66-7 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-1H-indol-6-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 129487-67-8 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-1-(2-propenyl)-1H-indol-6-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Updated Search

RN 129487-73-6 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-1-(hydroxyimino)-1H-inden-5-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 129487-74-7 HCAPLUS
CN Acetamide, N-[[2-oxo-3-(5,6,7,8-tetrahydro-2-naphthalenyl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 129487-75-8 HCAPLUS
CN Acetamide, N-[[2-oxo-3-(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 129487-76-9 HCAPLUS
CN Acetamide, N-[[3-(1H-indazol-5-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 129487-77-0 HCAPLUS
CN Acetamide, N-[[3-(1-ethyl-1H-indazol-5-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Updated Search



RN 129487-78-1 HCAPLUS
CN Acetamide, N-[[3-(1-acetyl-1H-indazol-5-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 129487-79-2 HCAPLUS
CN Acetamide, N-[[2-oxo-3-(1-propyl-1H-indazol-5-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 129487-80-5 HCAPLUS
CN Acetamide, N-[[3-(1-ethyl-2-methyl-1H-benzimidazol-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129487-81-6 HCAPLUS
CN Acetamide, N-[[2-oxo-3-(1-propyl-1H-benzimidazol-5-yl)-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Updated Search

Absolute stereochemistry.



RN 129487-82-7 HCAPLUS
CN 1H-Benzimidazole-1-carboxylic acid, 5-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-methyl-, 1,1-dimethylethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129487-83-8 HCAPLUS
CN Acetamide, N-[[3-(2-methyl-1H-benzimidazol-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129487-84-9 HCAPLUS
CN Acetamide, N-[[3-(1-acetyl-2-methyl-1H-benzimidazol-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

RN 129487-85-0 HCAPLUS
CN Acetamide, N-[[3-(1-formyl-1H-benzimidazol-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129487-86-1 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-1-(methylsulfonyl)-1H-indol-5-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 129491-47-0 HCAPLUS
CN Acetamide, N-[[3-(2-ethyl-2,3-dihydro-1-oxo-1H-inden-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129502-53-0 HCAPLUS
CN Acetamide, N-[[3-[1-(chloroacetyl)-2,3-dihydro-1H-indol-5-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 129567-77-7 HCAPLUS
CN Acetamide, N-[[3-(1-acetyl-2,3-dihydro-1H-indol-5-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 129567-78-8 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-1H-indol-5-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 129567-79-9 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-1-(2-methylpropyl)-1H-indol-5-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 129567-80-2 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-1-(2-propenyl)-1H-indol-5-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Updated Search



RN 129567-81-3 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-1H-inden-5-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 129567-82-4 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-1-oxo-1H-inden-5-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 129567-83-5 HCAPLUS
CN Acetamide, N-[[3-(1H-indazol-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129567-84-6 HCAPLUS
CN Acetamide, N-[[2-oxo-3-(1-propyl-1H-indazol-5-yl)-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 129567-85-7 HCAPLUS
CN Acetamide, N-[[3-(1-benzoyl-2,3-dihydro-1H-indol-5-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 129567-86-8 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-1-methyl-1H-indol-5-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 129567-87-9 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-2,2-dimethyl-1-oxo-1H-inden-5-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 129567-88-0 HCAPLUS
CN Acetamide, N-[[3-(1',3'-dihydro-1'-oxospiro[cyclopropane-1,2'-[2H]inden]-5'-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Updated Search



RN 129567-89-1 HCAPLUS
CN Acetamide, N-[[2-oxo-3-(5,6,7,8-tetrahydro-6,6-dimethyl-5-oxo-2-naphthalenyl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 129567-90-4 HCAPLUS
CN Acetamide, N-[[3-[1-[(acetyloxy)acetyl]-2,3-dihydro-1H-indol-5-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 129567-91-5 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-1-(2-thienylcarbonyl)-1H-indol-5-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 129567-95-9 HCAPLUS
CN Acetamide, N-[[3-(1-ethyl-2-methyl-1H-benzimidazol-5-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Updated Search



RN 129567-96-0 HCAPLUS
CN Acetamide, N-[[3-(1-ethyl-1H-indazol-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129567-98-2 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-1-(hydroxyacetyl)-1H-indol-5-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 129567-99-3 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-1-[(phenylmethoxy)acetyl]-1H-indol-5-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 129568-00-9 HCAPLUS
CN Acetamide, N-[[3-[1-(4-chlorobenzoyl)-2,3-dihydro-1H-indol-5-yl]-2-oxo-5-

Updated Search

oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 129568-01-0 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-1-(methoxyacetyl)-1H-indol-5-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 129568-02-1 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-1-(1-oxohexyl)-1H-indol-5-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 129568-71-4 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-1-(methylsulfonyl)-1H-indol-5-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

RN 129568-72-5 HCAPLUS
CN Acetamide, N-[[3-(1-acetyl-1H-indazol-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129645-53-0 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-1-propyl-1H-indol-5-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 129954-20-7 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-2-methyl-1-oxo-1H-inden-5-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 129954-21-8 HCAPLUS
CN Acetamide, N-[[3-(2-ethyl-2,3-dihydro-1-oxo-1H-inden-5-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Updated Search

L23 ANSWER 48 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1989:423501 HCAPLUS
DOCUMENT NUMBER: 111:23501
TITLE: Preparation of 5-(aminomethyl)-3-phenyl-2-oxazolidinone derivatives and antibacterial pharmaceuticals containing them
INVENTOR(S): Wang, Chia Lin J.; Wuonola, Mark A.
PATENT ASSIGNEE(S): du Pont de Nemours, E. I., and Co., USA
SOURCE: U.S., 13 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4801600	A	19890131	US 1987-106358	19871009
US 4921869	A	19900501	US 1988-233828	19880819
CA 1322001	A1	19930907	CA 1988-579301	19881004
AU 8823507	A1	19890413	AU 1988-23507	19881006
AU 613669	B2	19910808		
SU 1616518	A3	19901223	SU 1988-4356653	19881006
DK 8805628	A	19890410	DK 1988-5628	19881007
FI 8804610	A	19890410	FI 1988-4610	19881007
NO 8804467	A	19890410	NO 1988-4467	19881007
NO 172890	B	19930614		
NO 172890	C	19930922		
EP 311090	A1	19890412	EP 1988-116621	19881007
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 01132569	A2	19890525	JP 1988-252207	19881007
ZA 8807550	A	19900627	ZA 1988-7550	19881007
HU 53359	A2	19901028	HU 1988-5214	19881007
HU 202216	B	19910228		
IL 87972	A1	19930513	IL 1988-87972	19881007
US 4965268	A	19901023	US 1990-497213	19900315
US 4985429	A	19910115	US 1990-497211	19900315
US 5032605	A	19910716	US 1990-497212	19900315
US 5036093	A	19910730	US 1990-497214	19900315
US 5036092	A	19910730	US 1990-497215	19900315
US 5039690	A	19910813	US 1990-497216	19900315

PRIORITY APPLN. INFO.: US 1987-106358 A3 19871009
US 1988-233828 A3 19880819
OTHER SOURCE(S): CASREACT 111:23501; MARPAT 111:23501
GI



I

AB The title compds. I [B = NH2, NR3COR4, NR3S(O)uR5, N3; u = 1, 2; R3 = H,

Updated Search

alkyl, cycloalkyl; R4 = H, alkyl, alkenyl, cycloalkyl, OR5; R5 = alkyl; X = CH2, O, S, NR6; R6 = H, alkyl; n = 1-3; R1R2 = H2, H and OH, O, H and NR62, NOH, NOR5, NO2CR4, (4-methyl-1-piperazinyl)imino; also when n = 2, then X ≠ S; when n = 3, then X ≠ O, NR62], specifically the (-)-isomers or the racemic mixts., are prepared for the treatment of bacterial infections. 5-Aminoindan was converted to 5-isocyanatoindan by treatment with HCl gas and phosgene. A solution containing 0.78 g LiBr, 1.96 g Bu3P, and 200 mL xylene was added to a solution containing the latter product and 18.6 g (R)-glycidyl butyrate to give 26% (-)-[3-(2,3-dihydro-1H-inden-5-yl)-2-oxooxazolidin-5-yl]methyl butyrate. The butyrate (39 g) was treated with MeONa to give 82% of the corresponding alc., which (23 g) was mesylated to give 30.8 g mesylate which was subsequently treated with 12.9 g NaN3 to give (-)-5-(azidomethyl)-3-(2,3-dihydro-1H-inden-5-yl)-2-oxazolidinone. A mixture containing 400 mL glyme and 14.9 mL (MeO)3P was added to 25 g of azide; the mixture was heated to 65° for 1 h, and 10 mL 50% HCl were added and the solution was refluxed for 11 h to give the amine-HCl; the latter (8.7 g) was neutralized with NaOH in THF-H2O and treated with 4.14 g Ac2O to give (-)-I (R1R2 = H2, X = CH2, n = 1, B = NHAc) in 100% yield. The latter compound (7 g) was oxidized with CrO3 in aqueous AcOH to give 35% (-)-I (R1R2 = O, X = CH2, n = 1, B = NHAc) (II). The in vitro broth microdilution min. inhibitory concentration of II was 2-4 μg/mL and >128 μg/mL against Staphylococcus aureus and Escherichia coli, resp. In an acute lethal mouse model the dose of II required to protect 50% (EC50) of the test animals infected with S. aureus was 1.6 mg/kg. An aqueous suspension for oral administration (5 mL) contains 75 mg active agent, 200 mg Na CM-cellulose, 5 mg NaOBz, 1.0 g sorbitol solution, and 0.025 mL vanillin.

IT 120912-42-7P 120912-43-8P 120912-44-9P
120912-45-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as bactericide)

RN 120912-42-7 HCAPLUS

CN Acetamide, N-[[3-(2,3-dihydro-1H-inden-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 120912-43-8 HCAPLUS

CN Acetamide, N-[[3-(2,3-dihydro-1-oxo-1H-inden-5-yl)-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 120912-44-9 HCAPLUS
CN Acetamide, N-[[3-(2,3-dihydro-1-hydroxy-1H-inden-5-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 120912-45-0 HCAPLUS
CN Acetamide, N-[[3-[2,3-dihydro-1-[(4-methyl-1-piperazinyl)imino]-1H-inden-5-yl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L23 ANSWER 49 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1989:8198 HCAPLUS
DOCUMENT NUMBER: 110:8198
TITLE: Preparation of (aminomethyl)phenyloxazolidinones as antibacterial agents
INVENTOR(S): Gregory, Walter A.
PATENT ASSIGNEE(S): du Pont de Nemours, E. I., and Co., USA
SOURCE: U.S., 47 pp. Cont.-in-part of U.S. Ser. No. 676,745, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4705799	A	19871110	US 1985-803191	19851202
ZA 8404265	A	19860129	ZA 1984-4265	19840606

Updated Search

HU 196771	B	19890130	HU 1987-5132		19840606
IL 77230	A1	19900610	IL 1985-77230		19851204
CA 1275652	A2	19901030	CA 1988-580778		19881020
NO 8902178	A	19841210	NO 1989-2178		19890530
NO 169122	B	19920203			
NO 169122	C	19920513			
PRIORITY APPLN. INFO.:			US 1983-501897	A2	19830607
			US 1984-578332	A2	19840214
			US 1984-676745	A2	19841205
			CA 1984-455844	A3	19840605
			IL 1984-72028	A	19840605
			NO 1984-2273	A1	19840606

OTHER SOURCE(S): CASREACT 110:8198
GI



I

AB The title compds. [I; A = NO2, SH, alkylsulfonyl, -sulfinyl, -sulfenyl, etc.; B = N3, (substituted) amino; Y = H, F, Cl, Br, alkyl, NO2; or AY = O(CH2)nO where n = 1, 2, or 3], useful as antibacterial agents for mammals, are prepared A mixture of I (A = 4-MeSO2, B = OSO2C6H4Me-4, Y = H) (preparation given) and NaN3 in DMF was heated at 90-100° for 1 h to give I (A = 4-MeSO2, B = N3, Y = H). = H) (II). II showed a minimal inhibition concentration of 6.3 μg/mL against Staphylococcus epidermidis.

IT 96812-87-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antibacterial agent)

RN 96812-87-2 HCAPLUS

CN Acetamide, N-[[3-(1,3-benzodioxol-5-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



L23 ANSWER 50 OF 50 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	1985:437470 HCAPLUS
DOCUMENT NUMBER:	103:37470
TITLE:	Aminomethyloxooxazolidinylbenzene derivatives useful as antibacterial agents
INVENTOR(S):	Gregory, Walter Adelman
PATENT ASSIGNEE(S):	du Pont de Nemours, E. I., and Co. , USA
SOURCE:	Eur. Pat. Appl., 85 pp.

Updated Search

CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 127902	A2	19841212	EP 1984-106400	19840605
EP 127902	A3	19870902		
EP 127902	B1	19911016		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
ES 533097	A1	19850801	ES 1984-533097	19840604
AU 8429099	A1	19841213	AU 1984-29099	19840605
AU 583250	B2	19890427		
IL 72028	A1	19880531	IL 1984-72028	19840605
CA 1254213	A1	19890516	CA 1984-455844	19840605
AT 68490	E	19911115	AT 1984-106400	19840605
DK 8402795	A	19841208	DK 1984-2795	19840606
FI 8402273	A	19841208	FI 1984-2273	19840606
FI 83216	B	19910228		
FI 83216	C	19910610		
NO 8402273	A	19841210	NO 1984-2273	19840606
NO 163451	B	19900219		
NO 163451	C	19900530		
JP 60008277	A2	19850117	JP 1984-114710	19840606
HU 34462	A2	19850328	HU 1984-2192	19840606
HU 194194	B	19880128		
ZA 8404265	A	19860129	ZA 1984-4265	19840606
HU 196771	B	19890130	HU 1987-5132	19840606
SU 1505442	A3	19890830	SU 1984-3752502	19840606
ES 540812	A1	19880316	ES 1985-540812	19850228
SU 1426451	A3	19880923	SU 1986-4024095	19860207
CA 1275652	A2	19901030	CA 1988-580778	19881020
NO 8902178	A	19841210	NO 1989-2178	19890530
NO 169122	B	19920203		
NO 169122	C	19920513		

PRIORITY APPLN. INFO.:

US 1983-501897	A	19830607
US 1984-578332	A	19840214
CA 1984-455844	A3	19840605
EP 1984-106400	A	19840605
NO 1984-2273	A1	19840606

GI



I

AB The bactericidal oxazolidinones I [R = e.g. NO2, cyano, HO, HS, (un)substituted amines, alkylsulfonyl, alkylthio, alkylsulfinyl, aryl, sulfamoyl, alkoxy, or carbamoyl; R1 = H, F, Cl, Br, NO2; RR1 = alkylenedioxy, R2 = NH2, acylamino, N3, alkylsulfonylamino, alkylsulfinylamino] and their physiol. acceptable salts were prepared Thus, (±)-I (R = 4-MeSO2, R1 = H, R2 = Cl) was treated with NaI and the

Updated Search

resulting (±)-I (R2 = iodo) treated with NaN3 followed by hydrogenation in F3CCO2H to give (±)-I (R-4-MeSO2; R1 = H, R2 = NH2).F3CCO2H (II). The min. inhibitory concentration of II was 50 μg/mL against Staphylococcus epidermidis.

IT 96812-87-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 96812-87-2 HCAPLUS

CN Acetamide, N-[[3-(1,3-benzodioxol-5-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Updated Search